

Consumer safety considerations of skin and oral microbiome perturbation

McBain, Andrew J; Chapple, Iain

DOI:

[10.1128/CMR.00051-19](https://doi.org/10.1128/CMR.00051-19)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

McBain, AJ & Chapple, I 2019, 'Consumer safety considerations of skin and oral microbiome perturbation', *Clinical Microbiology Reviews*, vol. 32, no. 4, e00051-19. <https://doi.org/10.1128/CMR.00051-19>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Consumer Safety Considerations of Skin and Oral Microbiome Perturbation

Andrew J McBain^a, Catherine A O'Neill^a, Alejandro Amezcua^b, Laura J Price^b, Karoline Faust^c, Adrian Tett^d, Nicola Segata^d, Jonathan R Swann^e, Adrian M Smith^f, Barry Murphy^g, Mike Hoptroff^g, Gordon James^f, Yugandhar Reddy^h, Anindya Dasgupta^h, Tom Rossⁱ, Iain L Chapple^j, William G. Wade^k and Judith Fernandez-Piquer^{b*}

^aThe University of Manchester, UK

^bUnilever, Safety & Environmental Assurance Centre (SEAC), Colworth Science Park, Sharnbrook, UK

^cKU Leuven Department of Microbiology and Immunology, Rega Institute, Laboratory of Molecular Bacteriology, Leuven, Belgium

^dCentre for Integrative Biology, University of Trento, Trento Italy

^eDivision of Integrative Systems Medicine and Digestive Diseases, Imperial College London, UK

^fUnilever, Colworth Science Park, UK

^gUnilever, Port Sunlight, UK

^hUnilever, Bangalore, India

ⁱUniversity of Tasmania, Tasmania, Australia

^jThe University of Birmingham, UK

^kCentre for Host-Microbiome Interactions, Kings College London, UK

Key words. Consumer Safety, skin microbiome, oral microbiome, next generation sequencing, perturbation, personal care, hygiene, cosmetic, risk assessment.

*Current address: Upfield, Rotterdam, The Netherlands

For correspondence: Andrew J McBain, Division of Pharmacy and Optometry, Faculty of Biology, Medicine and Health, The University of Manchester, Oxford Road, Manchester M13 9PT, UK. Tel: 44 161 275 2360; Email: andrew.mcbain@manchester.ac.uk

| | |
|---|-----------|
| SUMMARY | 3 |
| INTRODUCTION | 3 |
| The human microbiome | 3 |
| The challenge of establishing causality | 4 |
| Targeting specific microbes with personal care products | 6 |
| Aims and Objectives | 7 |
| PROTECTION OF THE ORAL AND SKIN MICROBIOME FUNCTIONS TO PROMOTE HEALTH | 7 |
| The human microbiome in human health and wellbeing | 7 |
| Microbiome Composition <i>versus</i> function | 7 |
| FACTORS THAT CONTRIBUTE TO PERTURBATION OF THE SKIN AND ORAL MICROBIOMES | 9 |
| Microbiome stability as an indicator of health | 10 |
| Consumer products can alter microbiome composition or function | 12 |
| Microbiome individualisation | 13 |
| MEASURING CHANGES IN MICROBIOME COMPOSITION AND ACTIVITIES | 14 |
| Risks of pathogen colonisation | 14 |
| The human body as a microbial niche | 15 |
| Microbial diversity in health | 16 |
| The importance of bacterial abundance | 17 |
| Host-microbiota interactions | 17 |
| APPROACHES TO MEASURE CHANGES IN MICROBIOME COMPOSITION | 19 |
| Metagenomic profiling | 19 |
| Profiling of functional potential | 20 |
| Metatranscriptomic analyses | 21 |
| Metabolomic analyses | 23 |
| Mathematical modelling | 24 |
| CONCLUSIONS | 27 |
| ACKNOWLEDGMENTS | 27 |
| REFERENCES | 28 |
| AUTHOR BIOS | 41 |

38

39

40

41

42

43

44 **Summary**

45 Microbiomes associated with human skin and the oral cavity are uniquely exposed to personal care
46 regimes. Changes in the composition and activities of the microbial communities in these
47 environments can be utilised to promote consumer health benefits; for example by reducing the
48 numbers, composition or activities of microbes implicated in conditions such as acne, axillary
49 odour, dandruff and oral diseases. It is however important to ensure that innovative approaches for
50 microbiome manipulation do not unsafely disrupt the microbiome or compromise health, and where
51 major changes in the composition or activities of the microbiome may occur, these require
52 evaluation to ensure that critical biological functions are unaffected. This article is based on a two-
53 day workshop held at SEAC Unilever, Bedford, United Kingdom, involving 31 specialists in
54 microbial risk assessment, skin and oral microbiome research, microbial ecology, bioinformatics,
55 mathematical modelling and immunology. The first day focused on understanding the potential
56 implications of skin and oral microbiome perturbation, while approaches to characterise those
57 perturbations were discussed during the second day. This article discusses the factors that the panel
58 recommend are considered for personal care products that target the microbiomes of the skin and
59 the oral cavity.

60

61 **INTRODUCTION**

62

63 **The human microbiome**

64

65 The last two decades have seen the effective application of culture-independent methods to study
66 the human microbiota (the microbial cells) or microbiome (the associated DNA) (1). This has led to
67 a deeper and more comprehensive analysis of the diverse range of organisms that inhabit the body,
68 where a substantial proportion are not readily amenable to culture (2). In the process some but
69 certainly not all knowledge gaps have been addressed. High-throughput sequencing is currently
70 performed using a range of platforms including Illumina and Ion Torrent, which can rapidly
71 sequence millions of fragments of DNA in parallel (3). Hypervariable regions of the bacterial 16S
72 rRNA genes, or whole genome DNA is targeted to analyse complex microbial communities. For
73 16S amplicon sequencing in particular, bioinformatic analyses have been applied to cluster the
74 generated sequences according to their similarity to define different operational taxonomic units
75 (OTU), which are then compared to databases to reveal community composition. However, tools
76 such as DADA2 are being increasingly used to obtain exact sequence variants (4) giving greater
77 resolution (5). The often short sequencing reads and the large data volumes generated through NGS
78 presents challenges and taxonomic classification and relative abundances can vary depending on the

79 bioinformatic pipeline used (3). Microbiome research has nevertheless identified considerably
80 greater microbial diversity than had been previously characterised, overcoming some of the
81 limitations of culture including issues of non-culturability. Whilst microbiome research in humans
82 has focussed primarily on the gut, studies of the oral cavity (6-9) and skin (10-14) have facilitated
83 the deeper understanding of these sites, which are of particular relevance to personal care. The use
84 of personal care products can result in changes in microbiome that may be intentional or otherwise.
85 It is however important to note that "oral microbiome" and "skin microbiome" are simplified terms
86 referring to biogeography-dependent sets of communities where microbial composition and
87 activities can vary markedly depending on site.

88

89 **The challenge of establishing causality**

90

91 The human microbiome provides protection against pathogenic organisms (14) and can stimulate
92 the immune system (15, 16) and participate in the maintenance of different ecological niches
93 present in the body (17). Fluctuations in microbiome composition may therefore perturb beneficial
94 microbial functions with potential health implications for the host. The following section will
95 consider some notable diseases of the skin and the oral cavity where differentiating between cause
96 and association for microbiome composition has been challenging.

97 Atopic dermatitis (AD) is a chronic, relapsing inflammatory condition characterised by pruritis
98 (itchiness), wheals and flares, and in severe cases, broken, bleeding skin. A high *Staphylococcus*
99 *aureus* load has been reported to correlate with AD flares and *vice versa* in clinical studies
100 involving AD patients, where coagulase negative staphylococci (CoNS) were more abundant in
101 healthy controls (18). Colonisation with commensal staphylococci early in life appears to be
102 protective against the development of AD (19), and AD is also strongly associated with mutations
103 in the barrier protein, filaggrin (20). It has therefore been hypothesised that an abnormal epidermal

104 environment caused by a leaky skin barrier predisposes the skin to infection by exposing
105 environmental niches that would normally be inaccessible to *S. aureus*.

106 Unravelling the role of the microbiome in dermal diseases is confounded by the physiological
107 changes in host tissues that characterise the pathology. Acne vulgaris, for example, has been
108 associated with overgrowth of *Cutibacterium* (formerly *Propionibacterium*) *acnes*, but this
109 association is not necessarily causal. In addition, Acne vulgaris has been potentially linked to
110 changes in the dermal environment proposed to be driven by factors including a Western style diet,
111 which may influence signaling in the hair follicle resulting in overproduction of sebum (21). The
112 photodermatitis, polymorphic light eruption (PLE) that is characterised by a rash on exposure to
113 UV light has been associated with the abnormal expression of antimicrobial peptides in the skin,
114 (22) distinct from that seen in psoriasis or AD, suggesting a microbiota involvement. PLE is
115 however also associated with other changes in the immune system of the skin (23) (24). The
116 common inflammatory skin condition psoriasis has been associated with changes in the skin
117 microbiota (25) (26) but this association is not necessarily causal because the massive systemic
118 inflammatory response that is a feature of psoriasis may also profoundly influence the composition
119 of the skin microbiota (as reviewed by (27)).

120 Whilst the relationship between the oral microbiome and oral disease is arguably better understood,
121 knowledge gaps remain. Common conditions such as dental caries, gingivitis and periodontitis are
122 closely associated with potentially harmful changes in the composition and activities of the oral
123 microbiota (sometimes referred to as dysbiosis) (28) (29) that have environmental triggers. The
124 development of caries for example, is related to high intake of sugary foods and the consequent
125 production of lactic acid by caries-associated bacteria within the oral microbiome. This in turn
126 favours the growth of acid-tolerant, acidogenic organisms such as *Streptococcus mutans* which,
127 along with other oral bacteria, forms biofilms on the tooth surface (30). Acid produced by these
128 organisms can alter the balance of enamel demineralisation/remineralisation of the tooth, leading to

129 loss of mineral, and caries formation. In periodontitis, the persistent presence of subgingival
130 biofilms associated with poor oral hygiene can lead to inflammation and bone loss (31). The
131 pathology of periodontitis is largely caused by the host response and the primary risk factor is host
132 susceptibility (as reviewed by Wade (32)). However, certain species of bacteria favour inflamed
133 sites including *Porphyromonas gingivalis*, which can subvert the host response leading to a
134 “dysbiotic” microbiota, which further exacerbates lesions (33). Whilst the role of the host response
135 in periodontitis is well established, the roles of host response and microbiome for gingivitis merits
136 further research. Additionally, some reports suggest that oral bacteria can translocate from the
137 mouth into the systemic circulation and whilst causality has not been confirmed, periodontitis for
138 example, has been associated with other conditions such as coronary artery disease (34), rheumatoid
139 arthritis (35) and respiratory disease (36) (37).

140

141 **Targeting specific microbes with personal care products**

142

143 As well as investigating the role of the microorganisms present in health and disease, microbiome
144 research is increasingly being applied to investigate the fundamental biology of various skin
145 conditions (38), oral hygiene (39), dandruff (40), dental caries (41), acne (42) and periodontitis (28,
146 29) (Table 1). Recent advances in this field include improved knowledge of the bacterial and fungal
147 composition of the scalp in individuals with and without dandruff (43), and the identification of
148 bacteria involved in axillary (44) and oral (45) malodour. In addition, the importance of bacterial
149 strain variability in acne is also now appreciated; although the overall relative abundance of *C.*
150 *acnes* is comparable between acne and healthy individuals, significant differences at the strain level
151 have been observed (42). Manipulation of the compositional structure or function of skin and oral
152 microbiomes can potentially counteract certain undesirable health conditions where use of
153 probiotics, prebiotics and targeted antimicrobials may provide opportunities to restore the healthy
154 microbial composition of the skin (46) and oral cavity (47) (48). Manipulating innate immunity of
155 the skin and oral cavity is another route through which this could be achieved (39) (49)

156 **Aims and Objectives**

157
158 Whilst differentiating between association and causality remains a key issue in microbiome
159 research, the fact that in some cases interactions between the microbiome and the host play a role in
160 health and disease has been established (as previously reviewed (50)). It is therefore important that
161 the effect of personal care regimes on the microbiome receives adequate consideration.
162 Understanding of the factors that cause fluctuations in the microbiome is likely to contribute to the
163 development of novel approaches to understand potential links to undesirable health conditions, and
164 to the identification of microbiome-based biomarkers. It is in this context that the U.S. National
165 Academy of Sciences have discussed the need to incorporate interactions between the microbiome
166 and chemicals in assessing human health risks associated with environmental chemical exposure
167 (51). As understanding of the functional significance of the human microbiome progresses, and the
168 exploration of host-microbial interactions advances, understanding the effects of intentional
169 manipulation of the human microbiome in the context of human safety should be addressed.

170 In October 2016, a workshop was organised at Colworth Science Park in the UK including 31
171 specialists in the areas of microbial risk assessment, skin and the oral microbiome, microbial
172 ecology, bioinformatics, bacterial modelling and immunology. This manuscript emerged from
173 exploration of the areas discussed during the workshop. It considers factors that the panel agreed
174 require consideration when evaluating the safety of personal care products that aim to benefit the
175 consumer by affecting the composition or activities of the skin and oral microbiomes.

176 **PROTECTION OF THE ORAL AND SKIN MICROBIOME FUNCTIONS TO PROMOTE**
177 **HEALTH**

178
179 **The human microbiome in health and wellbeing**

180
181 Microbiotas associated with the oral mucosa and the skin help programme the human immune
182 system to recognise pathogens (52, 53), reduce the risk of invasion by undesired organisms (54),
183 produce vitamins and other metabolites such as short-chain fatty acids (55). In skin, Phenol Soluble

184 Modulins (PSMs) and bacteriocins (56) contribute to the ecological and structural maintenance of
185 the niche (54). Commensal skin organisms such as *S. epidermidis* and *C. acnes* use distinct
186 mechanisms to inhibit pathogens and maintain a healthy skin barrier. *S. epidermidis* produces
187 antimicrobial peptides which can reportedly control the growth of *S. aureus* (16) as well as serine
188 proteases to inhibit biofilm formation (16), fermentation products such as succinic acid that may
189 inhibit the overgrowth of the opportunistic pathogen *C. acnes* (46), and a unique form of
190 lipoteichoic acid that can inhibit skin inflammation during skin injury (57). *C. acnes* has also a
191 protective role as a commensal by converting sebum to free fatty acids, which in consequence
192 inhibit colonisation of opportunistic pathogens and contribute to the maintenance of an acidic skin
193 pH (46).

194 In the oral cavity, some streptococci generate hydrogen peroxide that can inhibit the caries-
195 associated bacterium *S. mutans* (58). The oral microbiome also has non-antimicrobial functions of
196 importance to health and disease where nitrate-reducing oral bacteria can convert dietary nitrate into
197 nitrites, which can influence cardiovascular health and blood pressure (59). Nutritional functions of
198 the oral microbiota are delivered by complex communities via cross feeding and syntrophy. For
199 example, streptococci have both glycosidic and endopeptidase activity, whilst species of *Prevotella*
200 and *Porphyromonas* species have endopeptidase activity and *Fusobacterium* and
201 *Peptostreptococcus* have aminopeptidase activity (60). Bearing in mind the roles of the skin and
202 oral microbiome that are currently understood and the fact that other activities remain unknown, the
203 maintenance and protection of the healthy functionality of the microbiome is an important
204 consideration when assessing the effect of personal care products.

205 **Microbiome Composition versus function**

206
207 Initiatives such as the Human Microbiome Project (HMP) (13) (53) (55) and other studies (14, 52,
208 61) have enhanced our understanding of baseline skin and oral microbial composition but the search
209 for attributes that define a healthy human microbiome continues. As part of the HMP, where 200

210 healthy individuals were examined, the “core” microbiome of different body sites, including saliva,
211 plaque, tongue and other oral tissues, ranged from zero to eight operational taxonomic units (OTUs)
212 when analysed for percentage prevalence of 100% compared to a higher range of 19-75 OTUs when
213 the percentage was lowered to 50% (62). Interpretation of the core microbiome to measure the
214 similarity of samples depends on the taxonomic resolution employed since samples may decrease in
215 apparent similarity when analysed to genus or OTUs compared to phylum level (61) (63) (64).
216 Whilst a specific group of microorganisms may be shared between individuals, inter-individual
217 variation may still be considerable at the species-level, and for the presence of rare microorganisms
218 (8, 14, 61). Care is therefore required when classifying microbiome composition as healthy or
219 otherwise, especially in the absence of species-level classification. This is of particular importance
220 in the oral cavity where different species within the same genera can have contrasting associations
221 between health and disease.

222 The functions provided by compositionally different microbiomes can be relatively similar between
223 individuals (55). Exploring which of these general functions are associated with health represents an
224 alternative to the concept of “healthy composition” (65). A proposed functionality-based definition
225 of a “healthy microbiome” involves three functions: those associated with health-related
226 housekeeping functions, human functions, and specialised functions (53). Housekeeping functions
227 involve energy production and the generation of metabolites and other requirements to maintain the
228 microbial community itself; human-associated functions comprise interactions with the host such as
229 developing and influencing the activity of the immune system and specialised functions include
230 regulation of the pH in a specific body site. A functional core has been described for metabolic
231 pathways detected in more than 75% of individuals (55). Pathway cores were identified for either
232 multiple or single body sites, reflecting the fact that some core functions are broadly distributed and
233 general to the human host whilst others are an adaptation to a specific body site. It should be noted
234 that core functions are not necessarily beneficial to the host. Among site-enriched pathways, nitrate

235 reduction has been identified as important in the oral cavity (55). These core pathways are generally
236 associated with microbial consortia. Such functional observations may provide further insights
237 when studied across populations and during longer temporal studies with a controlled microbial
238 change. If functional characterisation of the human microbiome can be achieved, measuring or
239 predicting the loss of a beneficial function or the introduction of an undesired function could be
240 used as a functional index during consumer safety assurance.

241 **FACTORS THAT CONTRIBUTE TO PERTURBATION OF THE SKIN AND ORAL** 242 **MICROBIOME**

243 **Microbiome stability as an indicator of health**

244 The stability of the microbiome over time in healthy individuals has been assessed (66). Temporal
245 stability has been explained as a state of equilibrium for a community regardless of the fact that
246 some microbes may at the same time be changing as response to disturbances (67). The ability of
247 the microbiome to remain balanced when exposed to a perturbation and to recover to a healthy
248 functional profile afterwards has also been proposed as a key feature of a healthy microbiome (53).
249 Despite their importance for understanding microbial community dynamics and responses to
250 perturbations, long-term longitudinal studies are still rare. However, based on the available
251 evidence, the composition of the human microbiome is relatively stable over time, with the main
252 variation within an individual being between body sites (13) and considerable temporal stability has
253 also been reported for the microbiome in healthy skin. Oh and colleagues (68) generated
254 metagenomic sequence data from longitudinal samples collected over 2 years and reported that
255 bacterial, fungal, and viral communities were largely stable over that time despite exposure to the
256 external environment. This stability was observed to be site-specific, with body sites harbouring
257 high microbiome diversity being more variable than low diversity (sebaceous) body sites.
258 Observations of temporal stability in the skin microbiome have been interpreted as evidence for
259 colonization resistance and used as the basis for clinical studies exploring skin microbiome in

260 disease states, where compositional changes in the microbiome have been reported. Costello *et al.*
261 (10) assessed the resilience of the skin microbiota by disinfecting plots on the forehead and left
262 volar (*i.e.* underside of) forearms of volunteers and then inoculating them with “foreign”
263 microbiotas (*i.e.* taken from the tongue and skin of other individuals). The microbiotas of forearm
264 plots (n= 16) that had been inoculated with tongue scrapings were more similar to tongue
265 communities than to those normally associated with the forearm in relative abundance between 2
266 and 8 h after inoculation. However, communities more similar to those normally associated with the
267 forehead, developed on forehead plots that had been similarly inoculated with tongue material. It
268 can be inferred therefore, that for some reason (potentially the presence of sebaceous lipids), the
269 forehead environment exerted a stronger selection pressure than the forearm. Furthermore,
270 following interpersonal and inter-gender reciprocal swaps of forehead and forearm microbiotas,
271 developing communities resembled the recipient rather than the donor, demonstrating the
272 importance of the environment and possibly, the action of endogenous mechanisms for
273 individualisation and microbiota perpetuation. The authors hypothesised that the stronger selection
274 at forehead sites was due to sebaceous secretions which, in contrast to dry sites like the volar
275 forearm, may have i) been more strongly selective and/or ii) could have supported the more rapid
276 recolonisation from appendageal structures, which is in agreement with the hypothesis outlined
277 above.

278 The oral microbiota may also remain stable over time in healthy individuals (6) although it is also
279 sufficiently malleable to be beneficially manipulated through hygienic intervention (39). It is
280 however important to consider what stability means when referring to a host-associated microbiota.
281 Belstrøm and colleagues collected saliva from five volunteers without oral disease every 4 h for 24
282 h, repeated this seven days later (69) and profiled the salivary microbiome. Whilst caution is
283 necessary given the small sample size, the author’s tentative conclusion was that “little or no
284 variation” within salivary microbiomes was observed over time. The oral cavity is a complex

285 environment with various distinct areas, and saliva, often purported to contain microorganisms
286 originating from multiple sites on the mouth may vary less in terms of microbiome composition
287 than for example, a tooth surface where in individuals following the recommended oral health
288 regime of twice daily brushing microbial abundance will be very low immediately after cleaning,
289 but can exceed 10^7 bacteria per cm^2 following regrowth.

290 Maintaining microbiome stability in healthy individuals will ensure that the beneficial microbial
291 functions are maintained (70) so the measurement of microbiome stability and its recovery
292 following disturbance are important in understanding potential risks. Whilst the human microbiome
293 is relatively stable, its composition can be altered both by pathologies such as gingivitis and
294 dandruff, or by treatment.

295 **Consumer products can alter microbiome composition or function**

296 The hypothesis that the skin microbiota, once established, is perpetuated by continuous endogenous
297 inoculation is supported by an investigation by Grice *et al.* (12) in which skin microbiota was
298 sampled using swabs and biopsies and profiled by high-throughput sequencing. An attractive
299 explanation is that secretions from sweat glands and the outward migration of differentiating skin
300 cells could transport bacteria cells from within appendageal structures continuously onto the skin
301 surface (as proposed by Kong *et al.* (71)). Daily hygiene regimens may however affect the
302 microbiome and some routines tooth brushing and hand washing do this intentionally to
303 respectively control reduce the risk of oral disease and to reduce the transmission of pathogens, (54,
304 72). Exposure to antimicrobials through the use of household and personal care products has shown
305 minimal long-term effects on the microbiome. In this respect, two human studies monitored how the
306 use of toothpaste, liquid and bar soap, and dishwashing liquid, with and without triclosan perturbed
307 the microbiome. The first study; a crossover control study involving healthy individuals, showed no
308 significant impact on human oral or gut microbiome composition during 4 months exposure to the
309 antibacterial compound triclosan (73). A longitudinal survey of the gut microbiota in infants and

310 mothers during the first year following birth also did not show major compositional changes or loss
311 of microbial diversity (74). It is highly likely that environmental modulation of the skin microbiota
312 has been occurring since the ancient origins of the microbiome for the skin through UV irradiation,
313 friction and washing, and for the oral cavity through diet, friction and cleaning. In personal care,
314 antiperspirants are used by approximately 50% of the global population and have been shown to
315 reduce bacterial load in the axilla. Individuals that do not use antiperspirants have been observed to
316 harbour greater axillary microbiome diversity than individuals that use antiperspirants do (75). For
317 antiperspirant and deodorant users who ceased use of product, an increase in Staphylococcaceae
318 was observed, in comparison to *Corynebacterium* species dominating in non-users. Perhaps
319 surprisingly, microbiome diversity was reported to be greater in antiperspirant users compared to
320 deodorant or non-users. In a separate study of nine cohorts, axillary diversity was similarly found to
321 be greater in antiperspirant (and deodorant) users compared to non-users (76). A recent study on
322 effect of cosmetic products on the microbiome of facial skin of high and low hydration groups
323 indicated that baseline bacterial diversity was greater in the low than that of high hydration group,
324 and that the use of cosmetic products decreased the differences between the two groups (38).

325 **Microbiome individualisation**

326 Evidence suggests that both environment and host genetics play important roles in determining the
327 composition of individual microbiomes. Salivary microbiome studies in twins indicate that overall
328 microbial abundance and some aspects of the microbial population structure are influenced by
329 heritability (77). With respect to the skin microbiome, Blekhman and colleagues (78) analysed
330 shotgun metagenomic data from the HMP, collecting data on host genetic variation for 93
331 individuals. They reported significant associations between host genetics and microbiome
332 composition for ten of the fifteen sites they assessed, including the oral cavity and the skin. Thus, as
333 well as extrinsic environmental factors, host genetics appears to play a role in the composition of
334 the oral and skin microbiotas, probably through immunological and other mechanisms. These

335 examples partly explain the variability between individuals observed in microbiome research (8)
336 and highlight the need to separate a significant change from individual variation when assessing
337 specific perturbations.

338 Extrinsic factors also influence the stability of the microbiome since activities such as smoking
339 tobacco have been shown to influence the composition of oral biofilms (79), suggesting that
340 smoking promotes the acquisition and colonisation of pathogenic bacteria. The development of
341 gingivitis and its progression from gingivitis to periodontitis and the promotion of dental plaque
342 biofilm colonisation partly depends on the host immune response (80). Gomez and colleagues (81)
343 illustrated the impact of host genetics through a human volunteer study involving a large cohort of
344 monozygotic and dizygotic twin children with and without active caries, with the aim of elucidating
345 the contributions of host genotype and shared environment on the oral microbiomes (supragingival
346 plaque) of children. They observed that similarity in oral microbiomes was higher between
347 monozygotic twins regardless of caries state, with certain taxa being identified as highly heritable
348 but that most of the variation was determined by the specific growth microenvironment. The caries
349 state however, was not associated with the more highly heritable bacteria suggesting that lifestyle,
350 diet and oral hygiene practices might outweigh parental heritability in establishment of a caries
351 associated microbiome. The more heritable species were detected at lower abundance with
352 increasing age and sugar consumption.

353 **MEASURING CHANGES IN MICROBIOME COMPOSITION AND ACTIVITIES**

354

355 **Risks of pathogen colonisation**

356 One of the beneficial activities of the microbiotas of the skin and oral cavity is the protection of the
357 host tissue from pathogens (as summarised in Figure 1). Perturbation of commensal communities
358 may be therefore a contributing factor to the pathogenesis of certain inflammatory conditions. In
359 some circumstances, overgrowth of commensal microorganisms with pathogenic potential
360 (pathobionts) or colonisation by external pathogenic organisms (transients) can cause disease. The

361 ability of transient organisms to colonise is likely to depend on the interactions with the
362 commensals residing at each specific body site. In this respect, microbial communities with more
363 competitive interactions than cooperative interactions are assumed to be more resilient in the sense
364 that cooperation causes coupling between species involving several species to change at the same
365 time and destabilise the system (82). In the mouth, loss of colonisation resistance through antibiotic
366 use can lead to infections by opportunistic pathogens such as *Candida* species and *S. aureus* (as
367 reviewed (83) (60)). In this regard, microbial changes that do not increase the opportunity for
368 pathogens to colonise are unlikely to adversely affect the wellbeing of the host.

369 **The human body as a microbial niche**

370 The skin and oral cavity present distinct environments, and ecological conditions *in situ*, have a
371 large influence on the compositional differences in microbiota between body sites. Oily, moist and
372 dry skin sites regulate nutrients and harbour specific microbial taxa (46, 52, 84). The mouth can be
373 broadly divided into different habitats: the gingiva and hard palate; the tongue and throat; and
374 dental plaque; each one colonised by a microbiome characteristic of the specific site (60). The
375 microbiota present in the oral cavity form biofilms by attaching to the different surfaces, which
376 confer spatial structure and provide the conditions required for different organisms to survive within
377 the community (85). The availability of oxygen is one of the drivers of microbiota composition and
378 in this context, a succession during the formation of dental plaque has been proposed whereby teeth
379 are initially colonised by facultative genera such as *Streptococcus*, with a shift to a microbial
380 community better adapted to anaerobic conditions, as the biofilm matures. Bacterial succession on
381 the tooth surface can also be strongly influenced by nutrient availability, mechanical stress and
382 saliva flow (6, 61, 86) and by binding of bacteria to proteins in the salivary pellicle coating the tooth
383 surface (87).

384 Interactions with the external environment can also drive selection. For example, an increase in
385 sugar intake or a reduction in saliva flow may induce a reduction in pH that allows the expansion of

386 aciduric organisms (86). Loss of moisture, changes in temperature and exposure to ultraviolet
387 radiation can also result in microbiota alteration in the skin (88). Similarly, changes in the spatial
388 structure may also influence the microbial community within a given body site (9, 88).

389

390 **Microbial diversity in health**

391 Several indices have been employed to differentiate microbiomes associated with health and
392 disease. Among these, microbial (ecological) diversity is frequently measured. Ecological diversity
393 can be measured as richness (the number of taxa present) and evenness (the abundance of microbial
394 constituents). Although not universally applicable, higher diversity has been associated with health
395 in specific contexts when considering that more diverse microbes may supply the host with
396 increased functional traits. However, microbial diversity on its own is not an accurate measure for
397 determining disease aetiology or health. Whilst reduced microbial diversity has frequently been
398 observed in conditions such as atopic dermatitis and psoriasis (89)-(90) this is not always the case,
399 for example, in both psoriatic and unaffected elbows (81) richness has been reported to be the same
400 whilst, an increase in bacterial diversity due to the rise of species of minor abundance has been
401 observed in gingivitis and periodontitis (64, 91). The measurement of diversity also does not
402 account for interactions among species and two microbiomes with the same level of diversity may
403 be different. It may therefore be more pertinent to observe the entire community of microbes
404 present and by extension how they are functioning, rather than relying on richness alone as a
405 predictor of disease (92).

406 **The importance of bacterial abundance**

407 Compositional studies of the skin and oral microbiomes have suggested that the load or abundance
408 of organisms can be more significant than their presence in the progression of disease. A 65%
409 increase in the proportion of *S. aureus* in atopic dermatitis sufferers at flare sites and partial
410 correlation between *S. aureus* abundance and disease severity have been reported (99). Similarly, *S.*

411 *epidermidis* was significantly more abundant during flares than post flares and in controls, although
412 the underlying reasoning for the increase in *S. epidermidis* was not determined (99). Several studies
413 have reported increased *C. acnes* abundance in acne compared to unaffected volunteers (93). Whilst
414 differences between the absolute numbers of bacteria between inflammatory acne, papules and
415 pustules have been reported there appears to be progressively higher bacterial loads vis-à-vis
416 severity of the disease (94). The use of quantification methods such as quantitative PCR has
417 revealed higher levels of *S. mutans* and *S. sobrinus* in children with caries compared to caries-free
418 children (95). In other oral diseases such as gingivitis, severity is better correlated with the plaque
419 load and maturity than with some specific bacteria (60). It should however be born in mind that
420 NGS is not well-suited to determining differences in bacterial absolute abundance (quantified
421 genetic or microbial load within a sample) such that two samples with identical relative abundance
422 (genetic representation of microbes within a sample ranked against all taxa in the sample) could
423 differ markedly in absolute abundance (96).

424 **Host-microbiota interactions**

425 Skin functions as a two-way barrier, which helps to preserve hydration levels and prevent entry of
426 noxious substances into the body. Skin function may be shaped by the commensal organisms and in
427 this respect, Naik *et al.* (97) demonstrated that germ-free mice had a weakened immune response to
428 the parasite *Leishmania major* compared to mice raised under specific pathogen-free conditions.
429 The impaired response in the germ-free mice could be rescued by colonisation with *S. epidermidis*
430 (97) implying a role for the microbiota in promoting host immunity. More recent evidence suggests
431 that the microbiota is fundamental to skin structure. Conventionally reared mice showed altered
432 gene expression compared with germ-free mice. Meisel *et al.* (98) reported that 2820 genes were
433 differentially regulated by microbial colonisation, which included genes associated not only with
434 the host immune response but also epidermal differentiation. Crucially, the expression of 9 genes
435 involved in the epidermal differentiation complex (EDC), a collection of genes involved in terminal

436 differentiation of keratinocytes (reviewed in (99)), was regulated by the microbiota. When the skin
437 of conventionally raised mice was compared to germ-free mice, differences in the balance of
438 proliferation and differentiation were observed. These data support the view that the microbiome
439 may be associated with the development of the skin architecture since the EDC has been implicated
440 in dermatological diseases such as psoriasis (reviewed in (100)). Various studies have shown that
441 the microbiota is associated with the outcome of the healing response when wounding breaches the
442 skin barrier. In broken skin the commensal microorganisms can behave as pathogens and
443 colonisation of wound sites can result in release of microbial metabolites that can further damage
444 host tissues (reviewed in (101)). It is therefore unsurprising that accelerated wound healing has been
445 observed in the absence of microbiota (102, 103) but it is also the case that the commensal
446 microbiota can produce antimicrobial peptides (AMPs) that can inhibit the invasion of wound sites
447 by pathogens (104). There is also evidence that *S. epidermidis* can inhibit the uncontrolled
448 inflammation sometimes associated with wounding. Part of the mechanism for this may involve the
449 inhibition of cytokine release by keratinocytes (57).

450 With respect to beneficial effects, *S. epidermidis* has been reported to augment tight junction
451 function in keratinocytes (105) where the interaction of keratinocyte monolayers with *S.*
452 *epidermidis* increased the trans-epithelial electrical resistance (a measure of tight junction function)
453 within a short time of exposure to this bacterium. Furthermore, toll-like receptor (TLR) ligands such
454 as lipoteichoic acid or peptidoglycan may augment tight junction function in keratinocyte
455 monolayers (106). These data suggest that skin commensals, like those of the gut, are probably
456 involved in many aspects of epithelial barrier homeostasis.

457 **MEASURING CHANGES IN MICROBIOME COMPOSITION**

458 Various data analysis methods are used in microbiome research that can objectively assess
459 microbial changes. This section describes the information that each technique provides and how it is
460 applied to characterise health and disease.

461 **Metagenomic profiling**

462 Studies employing both ribosomal profiling and metagenomics have sought to identify microbes
463 linked to either oral or cutaneous disease, whether at the community level or that of individual taxa.
464 Several studies have reported changes in the proportion of bacteria on the skin in psoriasis (25, 26,
465 89). Gao et al (25, 26) for example reported that Firmicutes were significantly overrepresented in
466 psoriasis lesions compared to uninvolved skin, whilst the *Actinobacteria* and *Propionibacterium*
467 species were reportedly present at significantly lower relative abundance in psoriatic lesions. Apart
468 from bacteria, the fungal genus *Malassezia* has also been associated with psoriasis (89, 107-110).
469 Altered microbial community profiles have also been reported in atopic dermatitis, where an
470 increased proportion of *Staphylococcus*, particularly *S. aureus* and *S. epidermidis*, were observed
471 during disease flares in comparison to baseline or post-treatment, and correlated with increased
472 disease severity (111-113).

473 In terms of the oral microbiota, changes in microbial composition have long been associated with
474 dental caries and periodontitis. For caries, sequence analysis has confirmed that bacteria other than
475 *S. mutans* are correlated with active caries (*Lactobacillus* and *Bifidobacterium*) and likewise several
476 taxonomic groups of bacteria are associated with periodontitis (28, 114-117). It is also clear that the
477 aetiology of disease also involves a complex interplay between the host and the resident microbial
478 communities that is yet to be fully explored. Applied to the study of psoriasis, such approaches
479 indicate that strain level features and associated functional variation may be pertinent to disease
480 (118).

481 This exploration of host-microbe interactions have been hindered by the fact that virulence and
482 pathogenic determinants could be partitioned at the sub-species or strain level. It is well established
483 that intra-species genomic features lead to phenotypic variability (113, 119-121). Ribosomal
484 genera-based profiling approaches lack strain level resolution. Several recent computational tools to

485 taxonomically (122-124) and functionally (125, 126) characterise individual members of the
486 microbiome at strain level resolution in metagenomic datasets have become available.

487 **Profiling of functional potential**

488 Whilst understanding the community structure of a microbiome and the relationship between
489 specific taxa and health or disease can be informative, knowledge of community function will
490 probably be most useful in understanding the effect of perturbing the microbiome. Shotgun
491 metagenomics provides the potential to access strain level taxonomic features and the potential
492 functional characteristics of the community which has until recently been computationally
493 challenging. This approach can be used for the investigation of functional traits, although it can
494 only reveal the functional potential of communities. It can also be used to profile viruses, which are
495 not amenable to ribosomal-based profiling. The oral microbiome have assessed disease states such
496 as caries or periodontal disease compared to healthy controls. Shi *et al.* (127) and Wang *et al.* (128)
497 reported that community function around bacterial chemotaxis and cell motility are increased in
498 disease compared to periodontal health. It has also been shown that in periodontal disease there is
499 an increase in metabolic pathway genes associated with fatty acid metabolism (129), as well as an
500 increase in genes associated with the metabolic degradation of nutrients (127) and those required for
501 growth in anaerobic conditions (129). Healthy communities have been shown to exhibit increased
502 functions in the areas of fatty acid biosynthesis, aspartate and homoserine metabolism, membrane
503 transport and signal transduction. Metagenomic studies of the skin are more difficult due to the low
504 bacterial density and small sample surfaces available (130). Mathieu *et al.* (131) consider the skin
505 microbiota as a complete organism, reporting a predominance of catabolic genes and the ability of
506 the skin bacteria to use the sugars, lipids and iron that are found on human skin. They also found
507 genes related to antibiotic resistance, as well as some linked to acid resistance, clearly a mechanism
508 for tolerance of the natural acidity of the skin. Oh *et al.* (17) have described a “functional core” of
509 around 30% of the community that can vary depending on the diversity and biogeography of the

510 differing skin microenvironments, which drives the functional capacity that is required by that
511 community. For example, dry sites were found to favour functional traits surrounding the citrate
512 cycle, and sebaceous sites showed increased function around glycolysis and ATP/GTP/NADH
513 dehydrogenase I. Whilst these metagenomic approaches exceed a simple inventory of taxa and
514 provide information on function and health/disease interrelationships, making judgements of
515 community functional traits by reference genome comparison should be undertaken with care.
516 There is a large genomic diversity that is just starting to be understood, for example the association
517 of only some *C. acnes* strains with acne vulgaris (123) (130). Further complicating the search for a
518 functional understanding of the microbiome is the identification of new genes from metagenomic
519 analysis approaches that are associated with health or disease, but which cannot be assigned to any
520 functional pathway.

521 **Metatranscriptomic analyses**

522 Shotgun transcriptomics can be used to determine the active functions of a microbiome (132),
523 especially as the community composition of a microbiome alone is not necessarily reflective of its
524 active community members (133). This is an emerging research area with less data available, and
525 challenges remain, for example in sampling sufficient mRNA material to enable analysis. However,
526 the transcriptomic profile of a community is dynamic and can easily change in the same biological
527 sample at different times as the microbiome responds continually to changing environmental and
528 host conditions. Metatranscriptomic studies applied to human microbiome are more limited in
529 comparison to metataxonomic/metagenomics surveys.

530 In comparison to the oral microbiome, metatranscriptomics of the skin is more challenging due to
531 the limitations of microbial biomass in the sample material. Kang and colleagues (132) analysed the
532 metatranscriptomics of patients with acne vulgaris versus healthy controls. *C. acnes* was reportedly
533 the most transcriptionally active organism and was predominant in both the healthy and diseased
534 samples. Further analysis of the gene expression profile of *C. acnes* in the samples identified that

535 the organism's activity on acne-affected skin was distinct from its activity on healthy skin.
536 Specifically, vitamin B12 biosynthesis pathway was observed to be significantly downregulated in
537 acne. Additionally, a model of how vitamin B12 modulates the transcriptional and metabolic
538 activities of *C. acnes* in acne pathogenesis was suggested. The model underlined how shotgun
539 metatranscriptomic approaches can enhance the understanding of disease pathogenesis. One of the
540 limitations of meta-transcriptome data is the final metabolic products generated by a microbial
541 community are not captured (133). In this respect, techniques such as proteomics, metabolomics,
542 and lipidomics can help to have a deeper functional characterisation of the microbiome.

543 Metatranscriptomics has been used in conjunction with metagenomics to investigate saliva from
544 individuals with caries and periodontitis to compare with saliva from orally disease-free individuals.
545 Belstrom *et al.* (69) identified 15 differentially expressed KEGG Orthologs (KOs) between
546 periodontitis or caries samples when compared with orally healthy controls. These included eight
547 carbohydrate metabolism-associated KOs that were downregulated in periodontal disease and two
548 KOs that were upregulated in caries associated with glycan biosynthesis and carbohydrate
549 metabolism. In addition, the same study observed that lipid metabolism was increased in healthy
550 samples when compared with dental caries and concluded that longitudinal studies may reveal that
551 screening salivary metabolic gene expression can identify oral diseases preclinically. However, it is
552 also clear that development of such diagnostics is at a very early stage and that overcoming the very
553 significant differences in complexity between the salivary and plaque microbiomes would be a
554 substantial technical and clinical challenge.

555 **Metabolomic analyses**

556 Microbial metabolites can have a direct impact on oral or skin health (*e.g.* short chain fatty acids
557 and sulphides in periodontal diseases, organic acids in dental caries) or they can enter and modulate
558 host metabolic processes. As such, metabolite exchange between the microbiome and host

559 represents one mechanism through which these systems communicate. Variation in the bacterial
560 species present can modulate the genetic library of the microbiome, changing its overall functional
561 capacity, its metabolite production, and the downstream impact on host health. However, different
562 species are known to possess similar or even the same metabolic traits. This functional redundancy
563 means that studying composition alone may be insufficient to accurately determine the overall
564 biotransformation capabilities of the microbiome and therefore its potential to modify host health.
565 Metabolic profiling (metabolomics/metabonomics) has emerged as a powerful tool for studying the
566 microbiota because it can ascertain the metabolic profile via low molecular weight compounds in a
567 sample. These metabolic signatures contain thousands of molecular small molecular weight
568 compounds reflecting biochemical events. This includes host metabolic processes but also those
569 performed by the resident microbes and products arising from interactions between the two. Studies
570 using metabolomics to directly assess the functional status of the skin microbiota are limited.
571 However, several studies have characterised the skin metabolome in a wider context. These have
572 used a variety of sample types including skin swabs, hydrogel micropatches (134), punch biopsies
573 and sweat. In one study analysing epidermal skin tissue, several bacterial-derived metabolites (135)
574 and bacterial substrates were observed, including *p*-cresol, a bacterial metabolite of tyrosine. This
575 demonstrates that these tissue samples can be informative for studying the skin microbiome. Skin
576 surface liquid extracts (sweat) represent another sample type of potential utility. These are complex
577 mixtures of secretions derived from eccrine, apocrine and/or sebaceous glands (depending of body
578 location) as well as from the microbiota inhabiting the skin (136). Attempts are being made to
579 optimise and standardise the collection and analysis of sweat and this may prove to be a useful
580 resource for studying the skin microbiota.

581 Metabolic profiling of gingival crevicular fluid (GCF) has been used to study the importance of
582 host-bacterial interactions in periodontal disease. Here, the depletion of anti-oxidants, degradation
583 of host cellular components and accumulation of bacterial products were seen in the disease state

584 (137) (138). Attempts have been made to integrate salivary bacterial and metabolic datasets to
585 identify metabolic products related to specific bacterial groups (139). Oral biofilms have also been
586 studied by capillary electrophoresis-mass spectrometry (CE-MS)-based metabolomics. This has
587 enabled the central carbon metabolic pathways to be investigated in the oral biofilm. One approach
588 is to measure these pathways in supragingival plaque before and after a glucose rinse. Glucose can
589 be degraded by bacteria to several metabolic products, including acetate, formate, lactate, and
590 succinate. Assessing the metabolic content of this plaque after the rinse provides information on the
591 functional capacity of the biofilm.

592 **Mathematical modelling**

593 Oral and skin microbial community dynamics are shaped by three broad factors: the host, the
594 environment and the community. The human host provides the microenvironment for the
595 community and may alter this environment through hygiene and other behaviours. The genetic
596 makeup of the host also influences the community's microenvironment. The surrounding
597 environment offers a large species pool from which immigration into the local community may take
598 place. Finally, community composition (richness, evenness and interactions) as well as history (e.g.
599 previous exposure to perturbations) may impact its dynamics.

600 A community model expresses in mathematical terms how selected factors influence community
601 dynamics. Community models thus allow prediction of the response of the community to short-term
602 (pulse) perturbations and altered conditions (press perturbations). Models can be coarse-grained or
603 detailed, describing populations or individuals. A general distinction can be made between
604 phenomenological models that predict community behaviour on the basis of immigration and
605 mortality rates, interaction strengths, growth rates and other parameters, and metabolic models that
606 take underlying molecular mechanisms of interactions into account. The generalized Lotka-Volterra

607 equation and its variants (140-142), but also individual-based models such as the neutral model
608 (143) and its extensions are examples of the former.

609 In the oral cavity, these models have to deal with the complication that most community members
610 can exist in both a free-floating planktonic state, as well as part of a biofilm, which may have
611 different growth rates, different access to nutrients and engage in different interactions. Previously,
612 Schroeder and colleagues (144) proposed a discrete and continuous version of a model that
613 describes the dynamics of both planktonic and sessile communities in drinking water pipes and
614 which may be adapted to model community dynamics in the oral cavity. The programming
615 language “gro”, which was designed for individual-based modelling of spatially structured
616 microbial communities, may also be of interest in this respect (145). This facilitates the modelling
617 of cell behaviours planktonically or in microcolonies or biofilms. A range of factors including
618 growth rates, cell-signalling, diffusing and chemotaxis can be factored in.

619 Metabolic models require the accurate reconstruction of each community member's metabolism
620 (146), which is a major hurdle because of lack of reliable and complete genome annotations and the
621 large percentage of unknown gene functions. Metabolic reconstructions may be quickly generated
622 automatically with tools such as ModelSEED or RAVEN (147) (148). This type of modelling
623 present some disadvantages such as the requirement for a tedious manual curation to ensure an
624 accurate reconstruction (149) and the assumption that community members are in a metabolic
625 steady state. This assumption is relaxed by some dynamic metabolic models which require kinetic
626 parameters such as compound uptake rates (146). The dynamic individual-based metabolic
627 modelling tools COMETS (150) and BacArena (151) additionally take spatial structure into
628 account, which is important to model biofilms. Metabolic models can also integrate meta-omics
629 data as additional constraints on metabolic fluxes (152). For example, gene expression data has
630 been used to validate metabolic models (153). Despite their promise, to the best of our knowledge,
631 metabolic models have only been applied to communities consisting of a small number of species.

632 Metabolic models of species grown alone and in pairs can be exploited to predict ecological
633 interactions (154). For instance, gut microbial interactions were predicted based on the semi-curated
634 reconstruction of 773 gut species (155). The extension of dynamic and spatial metabolic models to
635 more complex microbial communities is a promising field for future research.

636 Community-level metabolic networks are a simpler form of metabolic models, where metabolites
637 and reactions are represented as nodes and edges, respectively, but where stoichiometric
638 coefficients are not taken into account (156). They offer a framework for the straightforward
639 integration of meta-omics data as node or edge weights (157). While metabolic networks can handle
640 larger communities, they do not allow quantitative modelling (158).

641 Quantitative community models have parameters, which need to be determined through
642 measurements in well-controlled conditions. For instance, growth assays in mono- and co-culture
643 can provide growth rates and interaction strengths. Once a model is parameterized, it needs to be
644 validated experimentally. Such a validation consists of comparing the outcomes of experimental
645 perturbations with the outcomes predicted by the model. The model may undergo several rounds of
646 adjustment and validation until it reaches sufficient accuracy, or it may fail to be predictive because
647 important but unknown factors are not taken into account or the community dynamics are chaotic or
648 predominantly stochastic. A model that predicts community dynamics to an acceptable level of
649 accuracy can be applied to simulate the effects of yet untested perturbations on the community.

650

651 **CONCLUSIONS**

652 Perturbations of the microbiome can have positive and negative consequences for human health.
653 However, more knowledge is required to understand the extent of change that corresponds to the
654 maintenance of health and the establishment of disease states. Microbiome research is still in its
655 early stages and further studies to elucidate the nature of the functional and structural interactions

656 among microorganisms and with the host are required. Analysis of the gut microbiome is advancing
657 faster than that of the skin and oral microbiomes, where increasing research investment would help
658 to understand better the dynamics of those two specific body niches. Although mankind has been
659 manipulating its microbiome, often beneficially, through diet, hand washing and oral hygiene
660 practices both modern and historic, for hundreds if not thousands of years, the risks of manipulating
661 the microbiome through new technology innovation should be properly assessed and the
662 development of appropriate methods is required. Numerous factors should be considered when
663 assessing the safety of novel approaches to microbiome perturbation, and approaches need to be
664 developed to ensure that a compositional change delivers benefits whilst not compromising the
665 stability, diversity and immunological state required for healthy functionality of the microbiome.
666 These are summarised in Table 1 and Figure 1. To increase our understanding of the safety of
667 microbiome changes, multi-disciplinary research needs to move to a mechanistic understanding to
668 allow measurable elements specific to the oral and skin microbiome to be identified.

669 **ACKNOWLEDGEMENTS.** The authors acknowledge the inputs during workshop discussions
670 from the rest of the participants: Ilias Soumpasis, Jeff Temblay, Moira Parker, Sara Stewart, Chris
671 Quince, Elizabeth Grice, Gary Borisy, Iain Weddell, Ian Malcomber, Paul Barrett, Joanne Konkel,
672 Rebecca Ginger, Tom Curtis and Yvan LeMarc.

673 **Competing interests.** Alejandro Amezcuita, Laura J Price, Adrian M Smith, Barry Murphy, Mike
674 Hoptroff, Gordon James, Yugandhar Reddy, Anindya Dasgupta are employees of Unilever. Judith
675 Fernandez-Piquer was an employee of Unilever at the time of the workshop. All other authors:
676 nothing to declare.

677 **Authors' contributions.** All authors contributed to the preparation of this manuscript. AJM and JF-
678 P took the lead and finalised the text.

679 **REFERENCES**

- 680
681 1. Lederberg J, McCray AT. 2001. 'Ome sweet 'omics - A genealogical treasury of words.
682 *Scientist* 15:8-8.
- 683 2. Tlaskalová-Hogenová H, Stepánková R, Hudcovic T, Tucková L, Cukrowska B, Lodinová-
684 Zádňíková R, Kozáková H, Rossmann P, Bártová J, Sokol D, Funda DP, Borovská D,
685 Reháková Z, Sinkora J, Hofman J, Drastich P, Kokesová A. 2004. Commensal bacteria
686 (normal microflora), mucosal immunity and chronic inflammatory and autoimmune
687 diseases. *Immunol Lett* 93:97-108.
- 688 3. Yohe S, Thyagarajan B. 2017. Review of Clinical Next-Generation Sequencing. *Arch Pathol*
689 *Lab Med* 141:1544-1557.
- 690 4. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. 2016. DADA2:
691 High-resolution sample inference from Illumina amplicon data. *Nat Methods* 13:581-3.
- 692 5. Callahan BJ, McMurdie PJ, Holmes SP. 2017. Exact sequence variants should replace
693 operational taxonomic units in marker-gene data analysis. *ISME J* 11:2639-2643.
- 694 6. Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner ACR, Yu WH, Lakshmanan A, Wade WG.
695 2010. The human oral microbiome. *J Bacteriol* 192:5002-5017.
- 696 7. Segata N, Kinder Haake S, Mannon P, Lemon KP, Waldron L, Gevers D, Huttenhower C,
697 Izard J. 2012. Composition of the adult digestive tract bacterial microbiome based on seven
698 mouth surfaces, tonsils, throat and stool samples. *Genome Biol* doi:10.1186/gb-2012-13-6-
699 r42.
- 700 8. Utter DR, Mark Welch JL, Borisy GG. 2016. Individuality, stability, and variability of the
701 plaque microbiome. *Front Microbiol* 7.
- 702 9. Welch JLM, Rossetti BJ, Rieken CW, Dewhirst FE, Borisy GG. 2016. Biogeography of a
703 human oral microbiome at the micron scale. *Proc Natl Acad Sci USA* 113:E791-E800.
- 704 10. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. 2009. Bacterial
705 community variation in human body habitats across space and time. *Science* 326:1694-1697.
- 706 11. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, Bouffard GG, Blakesley
707 RW, Murray PR, Green ED, Turner ML, Segre JA. 2009. Topographical and temporal
708 diversity of the human skin microbiome. *Science* 324:1190-1192.
- 709 12. Grice EA, Kong HH, Renaud G, Young AC, Bouffard GG, Blakesley RW, Wolfsberg TG,
710 Turner ML, Segre JA. 2008. A diversity profile of the human skin microbiota. *Genome Res*
711 18:1043-1050.
- 712 13. Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, Chinwalla AT, Creasy HH,
713 Earl AM, Fitzgerald MG, Fulton RS, Giglio MG, Hallsworth-Pepin K, Lobos EA, Madupu

- 714 R, Magrini V, Martin JC, Mitreva M, Muzny DM, Sodergren EJ, Versalovic J, Wollam AM,
715 Worley KC, Wortman JR, Young SK, Zeng Q, Aagaard KM, Abolude OO, Allen-Vercoe E,
716 Alm EJ, Alvarado L, Andersen GL, Anderson S, Appelbaum E, Arachchi HM, Armitage G,
717 Arze CA, Ayvaz T, Baker CC, Begg L, Belachew T, Bhonagiri V, Bihan M, Blaser MJ,
718 Bloom T, Bonazzi V, Paul Brooks J, Buck GA, Buhay CJ, Busam DA, Campbell JL, et al.
719 2012. Structure, function and diversity of the healthy human microbiome. *Nature* 486:207-
720 214.
- 721 14. Oh J, Byrd AL, Park M, Kong HH, Segre JA. 2016. Temporal Stability of the Human Skin
722 Microbiome. *Cell* 165:854-866.
- 723 15. Prescott SL, Larcombe DL, Logan AC, West C, Burks W, Caraballo L, Levin M, Etten EV,
724 Horwitz P, Kozyrskyj A, Campbell DE. 2017. The skin microbiome: impact of modern
725 environments on skin ecology, barrier integrity, and systemic immune programming. *World*
726 *Allergy Organ J* 10:29.
- 727 16. Gallo RL. 2015. *S. epidermidis* influence on host immunity: more than skin deep. *Cell Host*
728 *Microbe* 17:143-4.
- 729 17. Oh J, Byrd AL, Deming C, Conlan S, Program NCS, Kong HH, Segre JA. 2014.
730 Biogeography and individuality shape function in the human skin metagenome. *Nature*
731 514:59-64.
- 732 18. Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, Shafiq F, Kotol PF,
733 Bouslimani A, Melnik AV, Latif H, Kim JN, Lockhart A, Artis K, David G, Taylor P, Streib
734 J, Dorrestein PC, Grier A, Gill SR, Zengler K, Hata TR, Leung DY, Gallo RL. 2017.
735 Antimicrobials from human skin commensal bacteria protect against *Staphylococcus aureus*
736 and are deficient in atopic dermatitis. *Sci Transl Med* 9.
- 737 19. Kennedy EA, Connolly J, Hourihane JO, Fallon PG, McLean WHI, Murray D, Jo JH, Segre
738 JA, Kong HH, Irvine AD. 2017. Skin microbiome before development of atopic dermatitis:
739 Early colonization with commensal staphylococci at 2 months is associated with a lower risk
740 of atopic dermatitis at 1 year. *J Allergy Clin Immunol* 139:166-172.
- 741 20. Morar N, Cookson WO, Harper JI, Moffatt MF. 2007. Filaggrin mutations in children with
742 severe atopic dermatitis. *J Invest Dermatol* 127:1667-72.
- 743 21. Melnik BC, Zouboulis CC. 2013. Potential role of FoxO1 and mTORC1 in the pathogenesis
744 of Western diet-induced acne. *Exp Dermatol* 22:311-5.
- 745 22. Patra V, Mayer G, Gruber-Wackernagel A, Horn M, Lembo S, Wolf P. 2018. Unique profile
746 of antimicrobial peptide expression in polymorphic light eruption lesions compared to
747 healthy skin, atopic dermatitis, and psoriasis. *Photodermatol Photoimmunol Photomed*
748 34:137-144.
- 749 23. Palmer RA, Friedmann PS. 2004. Ultraviolet radiation causes less immunosuppression in
750 patients with polymorphic light eruption than in controls. *J Invest Dermatol* 122:291-4.

- 751 24. Janssens AS, Pavel S, Tensen CP, Teunissen MB, Out-Luiting JJ, Willemze R, de Gruijl FR.
752 2009. Reduced IL-1Ra/IL-1 ratio in ultraviolet B-exposed skin of patients with polymorphic
753 light eruption. *Exp Dermatol* 18:212-7.
- 754 25. Fahlen A, Engstrand L, Baker BS, Powles A, Fry L. 2012. Comparison of bacterial
755 microbiota in skin biopsies from normal and psoriatic skin. *Arch Dermatol Res* 304:15-22.
- 756 26. Gao Z, Tseng CH, Strober BE, Pei Z, Blaser MJ. 2008. Substantial alterations of the
757 cutaneous bacterial biota in psoriatic lesions. *PLoS One* 3:e2719.
- 758 27. Griffiths CE, Barker JN. 2007. Pathogenesis and clinical features of psoriasis. *Lancet*
759 370:263-71.
- 760 28. Aas JA, Griffen AL, Dardis SR, Lee AM, Olsen I, Dewhirst FE, Leys EJ, Paster BJ. 2008.
761 Bacteria of dental caries in primary and permanent teeth in children and young adults. *J*
762 *Clinl Microbiol* 46:1407-1417.
- 763 29. Meuric V, Laine F, Boyer E, Le Gall-David S, Oger E, Bourgeois D, Bouchard P, Bardou-
764 Jacquet E, Turmel V, Bonnaure-Mallet M, Deugnier Y. 2017. Periodontal status and serum
765 biomarker levels in HFE haemochromatosis patients. A case-series study. *J Clin Periodontol*
766 44:892-897.
- 767 30. Kinane DF, Hajishengallis G. 2009. Polymicrobial infections, biofilms, and beyond. *J Clin*
768 *Periodontol* 36:404-5.
- 769 31. Kinane DF, Stathopoulou PG, Papapanou PN. 2017. Periodontal diseases. *Nat Rev Dis*
770 *Primers* 3:17038.
- 771 32. Wade WG. 2011. Has the use of molecular methods for the characterization of the human
772 oral microbiome changed our understanding of the role of bacteria in the pathogenesis of
773 periodontal disease? *J Clin Periodontol* 38 Suppl 11:7-16.
- 774 33. Hajishengallis G, Krauss JL, Liang S, McIntosh ML, Lambris JD. 2012. Pathogenic
775 microbes and community service through manipulation of innate immunity. *Adv Exp Med*
776 *Biol* 946:69-85.
- 777 34. Ryden L, Buhlin K, Ekstrand E, de Faire U, Gustafsson A, Holmer J, Kjellstrom B, Lindahl
778 B, Norhammar A, Nygren A, Nasman P, Rathnayake N, Svenungsson E, Klinge B. 2016.
779 Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the
780 PAROKRANK Study. *Circulation* 133:576-83.
- 781 35. Potempa J, Mydel P, Koziel J. 2017. The case for periodontitis in the pathogenesis of
782 rheumatoid arthritis. *Nat Rev Rheumatol* 13:606-620.
- 783 36. Muthu J, Muthanandam S, Mahendra J. 2016. Mouth the mirror of lungs: where does the
784 connection lie? *Front Med* 10:405-409.

- 785 37. Heo SM, Haase EM, Lesse AJ, Gill SR, Scannapieco FA. 2008. Genetic relationships
786 between respiratory pathogens isolated from dental plaque and bronchoalveolar lavage fluid
787 from patients in the intensive care unit undergoing mechanical ventilation. *Clin Infect Dis*
788 47:1562-70.
- 789 38. Lee HJ, Jeong SE, Lee S, Kim S, Han H, Jeon CO. 2018. Effects of cosmetics on the skin
790 microbiome of facial cheeks with different hydration levels. *Microbiol Open* 7:e00557.
- 791 39. Adams SE, Arnold D, Murphy B, Carroll P, Green AK, Smith AM, Marsh PD, Chen T,
792 Marriott RE, Brading MG. 2017. A randomised clinical study to determine the effect of a
793 toothpaste containing enzymes and proteins on plaque oral microbiome ecology. *Sci Rep*
794 7:43344.
- 795 40. Park T, Kim HJ, Myeong NR, Lee HG, Kwack I, Lee J, Kim BJ, Sul WJ, An S. 2017.
796 Collapse of human scalp microbiome network in dandruff and seborrhoeic dermatitis. *Exp*
797 *Dermatol* 26:835-838.
- 798 41. Rocas IN, Alves FR, Rachid CT, Lima KC, Assuncao IV, Gomes PN, Siqueira JF, Jr. 2016.
799 Microbiome of Deep Dentinal Caries Lesions in Teeth with Symptomatic Irreversible
800 Pulpitis. *PLoS One* 11:e0154653.
- 801 42. Fitz-Gibbon S, Tomida S, Chiu BH, Nguyen L, Du C, Liu M, Elashoff D, Erfe MC,
802 Loncaric A, Kim J, Modlin RL, Miller JF, Sodergren E, Craft N, Weinstock GM, Li H.
803 2013. *Propionibacterium acnes* strain populations in the human skin microbiome associated
804 with acne. *J Invest Dermatol* 133:2152-60.
- 805 43. Xu Z, Wang Z, Yuan C, Liu X, Yang F, Wang T, Wang J, Manabe K, Qin O, Wang X,
806 Zhang Y, Zhang M. 2016. Dandruff is associated with the conjoined interactions between
807 host and microorganisms. *Sci Rep* 6:24877.
- 808 44. James AG, Austin CJ, Cox DS, Taylor D, Calvert R. 2013. Microbiological and biochemical
809 origins of human axillary odour. *FEMS Microbiol Ecol* 83:527-40.
- 810 45. Kazor CE, Mitchell PM, Lee AM, Stokes LN, Loesche WJ, Dewhirst FE, Paster BJ. 2003.
811 Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy
812 patients. *J Clin Microbiol* 41:558-63.
- 813 46. Grice EA. 2014. The skin microbiome: potential for novel diagnostic and therapeutic
814 approaches to cutaneous disease. *Semin Cutan Med Surg* 33:98-103.
- 815 47. Seerangaiyan K, van Winkelhoff AJ, Harmsen HJM, Rossen JWA, Winkel EG. 2017. The
816 tongue microbiome in healthy subjects and patients with intra-oral halitosis. *J Breath Res*
817 11:036010.
- 818 48. Frias-Lopez J. 2015. Targeting specific bacteria in the oral microbiome. *Trends Microbiol*
819 23:527-8.

- 820 49. Mathapathi MS, Mallemalla P, Vora S, Iyer V, Tiwari JK, Chakraborty A, Majumdar A.
821 2017. Niacinamide leave-on formulation provides long-lasting protection against bacteria *in*
822 *vivo*. *Exp Dermatol* 26:827-829.
- 823 50. Meyle J, Chapple I. 2015. Molecular aspects of the pathogenesis of periodontitis.
824 *Periodontol* 2000 69:7-17.
- 825 51. NAS. 2018. National Academies of Sciences, Engineering, and Medicine. Environmental
826 Chemicals, the Human Microbiome, and Health Risk: A Research Strategy. doi:10.17226/24960:1-122, Washington, DC: The National Academies Press.
827
- 828 52. Grice EA, Segre JA. 2011. The skin microbiome. *Nature Rev Microbiol* 9:244-253.
- 829 53. Lloyd-Price J, Abu-Ali G, Huttenhower C. 2016. The healthy human microbiome. *Genome*
830 *Med* 8.
- 831 54. Kilian M, Chapple ILC, Hannig M, Marsh PD, Meuric V, Pedersen AML, Tonetti MS,
832 Wade WG, Zaura E. 2016. The oral microbiome - An update for oral healthcare
833 professionals. *Br Dent J* 221:657-666.
- 834 55. Lloyd-Price J, Mahurkar A, Rahnavard G, Crabtree J, Orvis J, Hall AB, Brady A, Creasy
835 HH, McCracken C, Giglio MG, McDonald D, Franzosa EA, Knight R, White O,
836 Huttenhower C. 2017. Strains, functions and dynamics in the expanded Human Microbiome
837 Project. *Nature* 550:61-66.
- 838 56. Christensen GJ, Bruggemann H. 2014. Bacterial skin commensals and their role as host
839 guardians. *Benef Microbes* 5:201-15.
- 840 57. Lai Y, Di Nardo A, Nakatsuji T, Leichtle A, Yang Y, Cogen AL, Wu Z-R, Hooper LV,
841 Schmidt RR, von Aulock S, Radek KA, Huang C-M, Ryan AF, Gallo RL. 2009. Commensal
842 bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. *Nature Med*
843 15:1377-1382.
- 844 58. Kreth J, Zhang Y, Herzberg MC. 2008. Streptococcal antagonism in oral biofilms:
845 *Streptococcus sanguinis* and *Streptococcus gordonii* interference with *Streptococcus*
846 *mutans*. *J Bacteriol* 190:4632-4640.
- 847 59. Kapil V, Haydar SMA, Pearl V, Lundberg JO, Weitzberg E, Ahluwalia A. 2013.
848 Physiological role for nitrate-reducing oral bacteria in blood pressure control. *Free Radical*
849 *Biol Med* 55:93-100.
- 850 60. Wade WG. 2013. The oral microbiome in health and disease. *Pharmacol Res* 69:137-43.
- 851 61. Hall MW, Singh N, Ng KF, Lam DK, Goldberg MB, Tenenbaum HC, Neufeld JD, G. Beiko
852 R, Senadheera DB. 2017. Inter-personal diversity and temporal dynamics of dental, tongue,
853 and salivary microbiota in the healthy oral cavity. *npj Biofilms Microbiomes* 3:2.

- 854 62. Huse SM, Ye Y, Zhou Y, Fodor AA. 2012. A core human microbiome as viewed through
855 16S rRNA sequence clusters. *PLoS One* 7:e34242.
- 856 63. Utter DR, Mark Welch JL, Borisy GG. 2016. Individuality, Stability, and Variability of the
857 Plaque Microbiome. *Front Microbiol* 7:564.
- 858 64. Kistler JO, Booth V, Bradshaw DJ, Wade WG. 2013. Bacterial community development in
859 experimental gingivitis. *PLoS One* 8:e71227.
- 860 65. Martiny JBH, Jones SE, Lennon JT, Martiny AC. 2015. Microbiomes in light of traits: A
861 phylogenetic perspective. *Science* 350.
- 862 66. Flores GE, Caporaso JG, Henley JB, Rideout JR, Domogala D, Chase J, Leff JW, Vazquez-
863 Baeza Y, Gonzalez A, Knight R, Dunn RR, Fierer N. 2014. Temporal variability is a
864 personalized feature of the human microbiome. *Genome Biol* 15:531.
- 865 67. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. 2012. Diversity, stability
866 and resilience of the human gut microbiota. *Nature* 489:220-30.
- 867 68. Oh J, Byrd AL, Park M, Program NCS, Kong HH, Segre JA. 2016. Temporal Stability of
868 the Human Skin Microbiome. *Cell* 165:854-66.
- 869 69. Belstrom D, Constancias F, Liu Y, Yang L, Drautz-Moses DI, Schuster SC, Kohli GS,
870 Jakobsen TH, Holmstrup P, Givskov M. 2017. Metagenomic and metatranscriptomic
871 analysis of saliva reveals disease-associated microbiota in patients with periodontitis and
872 dental caries. *NPJ Biofilms Microbiomes* 3:23.
- 873 70. Relman DA. 2012. The human microbiome: ecosystem resilience and health. *Nutr Rev* 70
874 Suppl 1:S2-9.
- 875 71. Kong HH. 2011. Skin microbiome: genomics-based insights into the diversity and role of
876 skin microbes. *Trends Mol Med* 17:320-8.
- 877 72. Babeluk R, Jutz S, Mertlitz S, Matiasek J, Klaus C. 2014. Hand hygiene - Evaluation of
878 three disinfectant hand sanitizers in a community setting. *PLoS ONE* 9.
- 879 73. Poole AC, Pischel L, Ley C, Suh G, Goodrich JK, Haggerty TD, Ley RE, Parsonnet J. 2016.
880 Crossover Control Study of the Effect of Personal Care Products Containing Triclosan on
881 the Microbiome. *mSphere* 1.
- 882 74. Ribado JV, Ley C, Haggerty TD, Tkachenko E, Bhatt AS, Parsonnet J. 2017. Household
883 triclosan and triclocarban effects on the infant and maternal microbiome. *EMBO Mol Med*
884 9:1732-1741.

- 885 75. Urban J, Fergus DJ, Savage AM, Ehlers M, Menninger HL, Dunn RR, Horvath JE. 2016.
886 The effect of habitual and experimental antiperspirant and deodorant product use on the
887 armpit microbiome. *PeerJ* 4:e1605.
- 888 76. Callewaert C, Hutapea P, Van de Wiele T, Boon N. 2014. Deodorants and antiperspirants
889 affect the axillary bacterial community. *Arch Dermatol Res* 306:701-10.
- 890 77. Demmitt BA, Corley RP, Huibregtse BM, Keller MC, Hewitt JK, McQueen MB, Knight R,
891 McDermott I, Krauter KS. 2017. Genetic influences on the human oral microbiome. *BMC*
892 *Genomics* 18.
- 893 78. Blekhman R, Goodrich JK, Huang K, Sun Q, Bukowski R, Bell JT, Spector TD, Keinan A,
894 Ley RE, Gevers D, Clark AG. 2015. Host genetic variation impacts microbiome
895 composition across human body sites. *Genome Biol* 16:191.
- 896 79. Kumar PS, Matthews CR, Joshi V, de Jager M, Aspiras M. 2011. Tobacco smoking affects
897 bacterial acquisition and colonization in oral biofilms. *Infect Immun* 79:4730-4738.
- 898 80. Silva N, Abusleme L, Bravo D, Dutzan N, Garcia-Sesnich J, Vernal R, Hernández M,
899 Gamonal J. 2015. Host response mechanisms in periodontal diseases. *Journal of Applied*
900 *Oral Science* 23:329-355.
- 901 81. Gomez A, Espinoza JL, Harkins DM, Leong P, Saffery R, Bockmann M, Torralba M,
902 Kuelbs C, Kodukula R, Inman J, Hughes T, Craig JM, Highlander SK, Jones MB, Dupont
903 CL, Nelson KE. 2017. Host Genetic Control of the Oral Microbiome in Health and Disease.
904 *Cell Host Microbe* 22:269-278 e3.
- 905 82. Coyte KZ, Schluter J, Foster KR. 2015. The ecology of the microbiome: Networks,
906 competition, and stability. *Science* 350:663-666.
- 907 83. Pankhurst CL. 2009. Candidiasis (oropharyngeal). *BMJ Clin Evid* 2009.
- 908 84. Grice EA. 2014. The skin microbiome: Potential for novel diagnostic and therapeutic
909 approaches to cutaneous disease. *Semin Cut Med Surg* 33:98-103.
- 910 85. Mark Welch JL, Rossetti BJ, Rieken CW, Dewhirst FE, Borisy GG. 2016. Biogeography of
911 a human oral microbiome at the micron scale. *Proc Natl Acad Sci U S A* 113:E791-800.
- 912 86. Marsh PD, Head DA, Devine DA. 2015. Ecological approaches to oral biofilms: Control
913 without killing. *Caries Res* 49:46-54.
- 914 87. Kolenbrander PE, Palmer RJ, Jr., Rickard AH, Jakubovics NS, Chalmers NI, Diaz PI. 2006.
915 Bacterial interactions and successions during plaque development. *Periodontol* 2000 42:47-
916 79.

- 917 88. Rosenthal M, Goldberg D, Aiello A, Larson E, Foxman B. 2011. Skin microbiota: Microbial
918 community structure and its potential association with health and disease. *InfectGenet Evol*
919 11:839-848.
- 920 89. Alekseyenko AV, Perez-Perez GI, De Souza A, Strober B, Gao Z, Bihan M, Li K, Methé
921 BA, Blaser MJ. 2013. Community differentiation of the cutaneous microbiota in psoriasis.
922 *Microbiome* 1:31.
- 923 90. Williams MR, Gallo RL. 2015. The role of the skin microbiome in atopic dermatitis. *Curr*
924 *Allergy Asthma Rep* 15:65.
- 925 91. Griffen AL, Beall CJ, Campbell JH, Firestone ND, Kumar PS, Yang ZK, Podar M, Leys EJ.
926 2012. Distinct and complex bacterial profiles in human periodontitis and health revealed by
927 16S pyrosequencing. *ISME J* 6:1176-85.
- 928 92. Zaneveld JR, McMinds R, Vega Thurber R. 2017. Stress and stability: applying the Anna
929 Karenina principle to animal microbiomes. *Nat Microbiol* 2:17121.
- 930 93. Akaza N, Akamatsu H, Numata S, Yamada S, Yagami A, Nakata S, Matsunaga K. 2016.
931 Microorganisms inhabiting follicular contents of facial acne are not only *Propionibacterium*
932 but also *Malassezia* spp. *J Dermatol.* 43:906-11
- 933 94. Leeming JP, Holland KT, Cuncliffe WJ. 1988. The microbial colonization of inflamed acne
934 vulgaris lesions. *Br J Dermatol* 118:203-8.
- 935 95. Choi EJ, Lee SH, Kim YJ. 2009. Quantitative real-time polymerase chain reaction for
936 *Streptococcus mutans* and *Streptococcus sobrinus* in dental plaque samples and its
937 association with early childhood caries. *Int J Paediatr Dent* 19:141-7.
- 938 96. Tkacz A, Hortala M, Poole PS. 2018. Absolute quantitation of microbiota abundance in
939 environmental samples. *Microbiome* 6:110.
- 940 97. Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, Deming C,
941 Quinones M, Koo L, Conlan S, Spencer S, Hall JA, Dzutsev A, Kong H, Campbell DJ,
942 Trinchieri G, Segre JA, Belkaid Y. 2012. Compartmentalized control of skin immunity by
943 resident commensals. *Science* 337:1115-9.
- 944 98. Meisel JS, Sfyroera G, Bartow-McKenney C, Gimblet C, Bugayev J, Horwinski J, Kim B,
945 Brestoff JR, Tyldsley AS, Zheng Q, Hodkinson BP, Artis D, Grice EA. 2018. Commensal
946 microbiota modulate gene expression in the skin. *Microbiome* 6:20.
- 947 99. Henry J, Toulza E, Hsu CY, Pellerin L, Balica S, Mazereeuw-Hautier J, Paul C, Serre G,
948 Jonca N, Simon M. 2012. Update on the epidermal differentiation complex. *Front Biosci*
949 (Landmark Ed) 17:1517-32.
- 950 100. Abhishek S, Palamadai Krishnan S. 2016. Epidermal Differentiation Complex: A Review on
951 Its Epigenetic Regulation and Potential Drug Targets. *Cell J* 18:1-6.

- 952 101. Eming SA, Krieg T, Davidson JM. 2007. Inflammation in wound repair: molecular and
953 cellular mechanisms. *J Invest Dermatol* 127:514-25.
- 954 102. Canesso MC, Vieira AT, Castro TB, Schirmer BG, Cisalpino D, Martins FS, Rachid MA,
955 Nicoli JR, Teixeira MM, Barcelos LS. 2014. Skin wound healing is accelerated and scarless
956 in the absence of commensal microbiota. *J Immunol* 193:5171-80.
- 957 103. Zhang J, Guan J, Niu X, Hu G, Guo S, Li Q, Xie Z, Zhang C, Wang Y. 2015. Exosomes
958 released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous
959 wound healing by promoting collagen synthesis and angiogenesis. *J Transl Med* 13:49.
- 960 104. Wanke I, Steffen H, Christ C, Krismer B, Gotz F, Peschel A, Schaller M, Schittek B. 2011.
961 Skin commensals amplify the innate immune response to pathogens by activation of distinct
962 signaling pathways. *J Invest Dermatol* 131:382-90.
- 963 105. Ohnemus U, Kohrmeyer K, Houdek P, Rohde H, Wladykowski E, Vidal S, Horstkotte MA,
964 Aepfelbacher M, Kirschner N, Behne MJ, Moll I, Brandner JM. 2008. Regulation of
965 epidermal tight-junctions (TJ) during infection with exfoliative toxin-negative
966 *Staphylococcus* strains. *Journal of Investigative Dermatology* 128:906-16.
- 967 106. Yuki T, Yoshida H, Akazawa Y, Komiya A, Sugiyama Y, Inoue S. 2011. Activation of
968 TLR2 enhances tight junction barrier in epidermal keratinocytes. *J Immunol* 187:3230-7.
- 969 107. Rudramurthy SM, Honnavar P, Chakrabarti A, Dogra S, Singh P, Handa S. 2014.
970 Association of *Malassezia* species with psoriatic lesions. *Mycoses* 57:483-488.
- 971 108. Fahlén A, Engstrand L, Baker BS, Powles A, Fry L. 2012. Comparison of bacterial
972 microbiota in skin biopsies from normal and psoriatic skin. *ArchDermatolResh* 304:15-22.
- 973 109. Gao Z, Tseng CH, Strober BE, Pei Z, Blaser MJ. 2008. Substantial alterations of the
974 cutaneous bacterial biota in psoriatic lesions. *PLoS ONE* 3.
- 975 110. Takemoto A, Cho O, Morohoshi Y, Sugita T, Muto M. 2015. Molecular characterization of
976 the skin fungal microbiome in patients with psoriasis. *J Dermatol* 42:166-170.
- 977 111. Chng KR, Tay ASL, Li C, Ng AHQ, Wang J, Suri BK, Matta SA, McGovern N, Janela B,
978 Wong XFCC, Sio YY, Au BV, Wilm A, De Sessions PF, Lim TC, Tang MBY, Ginhoux F,
979 Connolly JE, Lane EB, Chew FT, Common JEA, Nagarajan N. 2016. Whole metagenome
980 profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare. *Nature*
981 *Microbiol* 1:16106.
- 982 112. Kennedy EA, Connolly J, Hourihane JOB, Fallon PG, McLean WHI, Murray D, Jo J-H,
983 Segre JA, Kong HH, Irvine AD. 2017. Skin microbiome before development of atopic
984 dermatitis: Early colonization with commensal staphylococci at 2 months is associated with
985 a lower risk of atopic dermatitis at 1 year. *J Allergy Clin Immunol* 139:166-172.

- 986 113. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC,
987 Komarow HD, Mullikin J, Thomas J, Blakesley R, Young A, Chu G, Ramsahoye C, Lovett
988 S, Han J, Legaspi R, Sison C, Montemayor C, Gregory M, Hargrove A, Johnson T, Riebow
989 N, Schmidt B, Novotny B, Gupta J, Benjamin B, Brooks S, Coleman H, Ho SL, Schandler
990 K, Stantripop M, Maduro Q, Bouffard G, Dekhtyar M, Guan X, Masiello C, Maskeri B,
991 McDowell J, Park M, Vemulapalli M, Murray PR, Turner ML, Segre JA. 2012. Temporal
992 shifts in the skin microbiome associated with disease flares and treatment in children with
993 atopic dermatitis. *Genome Res* 22:850-859.
- 994 114. Abusleme L, Dupuy AK, Dutzan N, Silva N, Burleson JA, Strausbaugh LD, Gamonal J,
995 Diaz PI. 2013. The subgingival microbiome in health and periodontitis and its relationship
996 with community biomass and inflammation. *ISME J* 7:1016-1025.
- 997 115. Hong BY, Araujo MVF, Strausbaugh LD, Terzi E, Ioannidou E, Diaz PI. 2015. Microbiome
998 profiles in periodontitis in relation to host and disease characteristics. *PLoS ONE* 10.
- 999 116. Kirst ME, Li EC, Alfant B, Chi YY, Walker C, Magnusson I, Wang GP. 2015. Dysbiosis
1000 and alterations in predicted functions of the subgingival microbiome in chronic
1001 periodontitis. *Appl Environ Microbiol* 81:783-793.
- 1002 117. Peterson SN, Snesrud E, Liu J, Ong AC, Kilian M, Schork NJ, Bretz W. 2013. The Dental
1003 Plaque Microbiome in Health and Disease. *PLoS ONE* 8.
- 1004 118. Tett A, Pasolli E, Farina S, Truong DT, Asnicar F, Zolfo M, Beghini F, Armanini F, Jousson
1005 O, De Sanctis V, Bertorelli R, Girolomoni G, Cristofolini M, Segata N. 2017. Unexplored
1006 diversity and strain-level structure of the skin microbiome associated with psoriasis. *NPJ*
1007 *Biofilms Microbiomes* 3:14.
- 1008 119. Mira A, Martín-Cuadrado AB, D'Auria G, Rodríguez-Valera F. 2010. The bacterial pan-
1009 genome: A new paradigm in microbiology. *Inter Microbiol* 13:45-57.
- 1010 120. Mustapha MM, Marsh JW, Krauland MG, Fernandez JO, de Lemos APS, Dunning Hotopp
1011 JC, Wang X, Mayer LW, Lawrence JG, Hiller NL, Harrison LH. 2015. Genomic
1012 Epidemiology of Hypervirulent Serogroup W, ST-11 *Neisseria meningitidis*. *EBioMedicine*
1013 2:1447-1455.
- 1014 121. Zhu A, Sunagawa S, Mende DR, Bork P. 2015. Inter-individual differences in the gene
1015 content of human gut bacterial species. *Genome Biol* 16.
- 1016 122. Luo C, Knight R, Siljander H, Knip M, Xavier RJ, Gevers D. 2015. ConStrains identifies
1017 microbial strains in metagenomic datasets. *Nature Biotechnol* 33:1045-1052.
- 1018 123. Truong DT, Tett A, Pasolli E, Huttenhower C, Segata N. 2017. Microbial strain-level
1019 population structure & genetic diversity from metagenomes. *Genome Res* 27:626-638.
- 1020 124. Zolfo M, Tett A, Jousson O, Donati C, Segata N. 2017. MetaMLST: Multi-locus strain-level
1021 bacterial typing from metagenomic samples. *Nucleic Acids Res* 45:e7.

- 1022 125. Quince C, Connelly S, Raguideau S, Alneberg J, Shin SG, Collins G, Eren AM. 2016. De
1023 novo extraction of microbial strains from metagenomes reveals intra-species niche
1024 partitioning. bioRxiv doi:10.1101/073825.
- 1025 126. Scholz M, Ward DV, Pasolli E, Tolio T, Zolfo M, Asnicar F, Truong DT, Tett A, Morrow
1026 AL, Segata N. 2016. Strain-level microbial epidemiology and population genomics from
1027 shotgun metagenomics. Nat Methods 13:435-438.
- 1028 127. Shi B, Chang M, Martin J, Mitreva M, Lux R, Klokkevold P, Sodergren E, Weinstock GM,
1029 Haake SK, Li H. 2015. Dynamic changes in the subgingival microbiome and their potential
1030 for diagnosis and prognosis of periodontitis. MBio 6:e01926-14.
- 1031 128. Wang J, Qi J, Zhao H, He S, Zhang Y, Wei S, Zhao F. 2013. Metagenomic sequencing
1032 reveals microbiota and its functional potential associated with periodontal disease. Sci Rep
1033 3:1843.
- 1034 129. Xu P, Gunsolley J. 2014. Application of metagenomics in understanding oral health and
1035 disease. Virulence 5:424-32.
- 1036 130. Mathieu A, Vogel TM, Simonet P. 2014. The future of skin metagenomics. Res Microbiol
1037 165:69-76.
- 1038 131. Mathieu A, Delmont TO, Vogel TM, Robe P, Nalin R, Simonet P. 2013. Life on human
1039 surfaces: skin metagenomics. PLoS One 8:e65288.
- 1040 132. Kang D, Shi B, Erfe MC, Craft N, Li H. 2015. Vitamin B12 modulates the transcriptome of
1041 the skin microbiota in acne pathogenesis. Sci Transl Med 7:293ra103.
- 1042 133. Solbiati J, Frias-Lopez J. 2018. Metatranscriptome of the Oral Microbiome in Health and
1043 Disease. J Dent Res 97:492-500.
- 1044 134. Dutkiewicz EP, Chiu HY, Urban PL. 2017. Probing Skin for Metabolites and Topical Drugs
1045 with Hydrogel Micropatches. Anal Chem 89:2664-2670.
- 1046 135. Kuehne A, Hildebrand J, Soehle J, Wenck H, Terstegen L, Gallinat S, Knott A, Winnefeld
1047 M, Zamboni N. 2017. An integrative metabolomics and transcriptomics study to identify
1048 metabolic alterations in aged skin of humans *in vivo*. BMC Genomics 18:169.
- 1049 136. Hussain JN, Mantri N, Cohen MM. 2017. Working Up a Good Sweat - The Challenges of
1050 Standardising Sweat Collection for Metabolomics Analysis. Clin Biochem Rev 38:13-34.
- 1051 137. Barnes VM, Teles R, Trivedi HM, Devizio W, Xu T, Mitchell MW, Milburn MV, Guo L.
1052 2009. Acceleration of purine degradation by periodontal diseases. J Dent Res 88:851-5.

- 1053 138. Barnes VM, Kennedy AD, Panagakos F, Devizio W, Trivedi HM, Jonsson T, Guo L, Cervi
1054 S, Scannapieco FA. 2014. Global metabolomic analysis of human saliva and plasma from
1055 healthy and diabetic subjects, with and without periodontal disease. PLoS One 9:e105181.
- 1056 139. De Filippis F, Vannini L, La Storia A, Laghi L, Piombino P, Stellato G, Serrazanetti DI,
1057 Gozzi G, Turrone S, Ferrocino I, Lazzi C, Di Cagno R, Gobbetti M, Ercolini D. 2014. The
1058 same microbiota and a potentially discriminant metabolome in the saliva of omnivore, ovo-
1059 lacto-vegetarian and Vegan individuals. PLoS One 9:e112373.
- 1060 140. Fisher CK, Mehta P. 2014. Identifying keystone species in the human gut microbiome from
1061 metagenomic timeseries using sparse linear regression. PLoS ONE 9.
- 1062 141. Marino S, Baxter NT, Huffnagle GB, Petrosino JF, Schloss PD. 2014. Mathematical
1063 modeling of primary succession of murine intestinal microbiota. Proceedings of the National
1064 Academy of Sciences of the United States of America 111:439-444.
- 1065 142. Stein RR, Bucci V, Toussaint NC, Buffie CG, Räscht G, Pamer EG, Sander C, Xavier JB.
1066 2013. Ecological Modeling from Time-Series Inference: Insight into Dynamics and Stability
1067 of Intestinal Microbiota. PLoS Computational Biology 9: e1003388.
- 1068 143. Rosindell J, Hubbell SP, Etienne RS. 2011. The Unified Neutral Theory of Biodiversity and
1069 Biogeography at Age Ten. Trends in Ecology and Evolution 26:340-348.
- 1070 144. Schroeder JL, Lunn M, Pinto AJ, Raskin L, Sloan WT. 2015. Probabilistic models to
1071 describe the dynamics of migrating microbial communities. PLoS One 10:e0117221.
- 1072 145. Jang SS, Oishi KT, Egbert RG, Klavins E. 2012. Specification and simulation of synthetic
1073 multicelled behaviors. ACS Synth Biol 1:365-74.
- 1074 146. Gottstein W, Olivier BG, Bruggeman FJ, Teusink B. 2016. Constraint-based stoichiometric
1075 modelling from single organisms to microbial communities. Journal of the Royal Society
1076 Interface 13.
- 1077 147. Devoid S, Overbeek R, DeJongh M, Vonstein V, Best AA, Henry C. 2013. Automated
1078 genome annotation and metabolic model reconstruction in the SEED and Model SEED.
1079 Methods Mol Biol 985:17-45.
- 1080 148. Agren R, Liu L, Shoaie S, Vongsangnak W, Nookaew I, Nielsen J. 2013. The RAVEN
1081 toolbox and its use for generating a genome-scale metabolic model for *Penicillium*
1082 *chrysogenum*. PLoS Comput Biol 9:e1002980.
- 1083 149. Thiele I, Palsson BO. 2010. A protocol for generating a high-quality genome-scale
1084 metabolic reconstruction. Nat Protoc 5:93-121.
- 1085 150. Harcombe WR, Riehl WJ, Dukovski I, Granger BR, Betts A, Lang AH, Bonilla G, Kar A,
1086 Leiby N, Mehta P, Marx CJ, Segrè D. 2014. Metabolic resource allocation in individual

- 1087 microbes determines ecosystem interactions and spatial dynamics. *Cell Reports* 7:1104-
1088 1115.
- 1089 151. Bauer E, Zimmermann J, Baldini F, Thiele I, Kaleta C. 2017. BacArena: Individual-based
1090 metabolic modeling of heterogeneous microbes in complex communities. *PLoS Comput*
1091 *Biol* 13:e1005544.
- 1092 152. Kim MK, Lun DS. 2014. Methods for integration of transcriptomic data in genome-scale
1093 metabolic models. *Comput Struct Biotechnol J* 11:59-65.
- 1094 153. Henry CS, Bernstein HC, Weisenhorn P, Taylor RC, Lee JY, Zucker J, Song HS. 2016.
1095 Microbial Community Metabolic Modeling: A Community Data-Driven Network
1096 Reconstruction. *J Cell Physiol* 231:2339-45.
- 1097 154. Freilich S, Zarecki R, Eilam O, Segal ES, Henry CS, Kupiec M, Gophna U, Sharan R,
1098 Ruppin E. 2011. Competitive and cooperative metabolic interactions in bacterial
1099 communities. *Nat Commun* 2:589.
- 1100 155. Magnusdottir S, Heinken A, Kutt L, Ravcheev DA, Bauer E, Noronha A, Greenhalgh K,
1101 Jager C, Baginska J, Wilmes P, Fleming RM, Thiele I. 2017. Generation of genome-scale
1102 metabolic reconstructions for 773 members of the human gut microbiota. *Nat Biotechnol*
1103 35:81-89.
- 1104 156. Greenblum S, Chiu HC, Levy R, Carr R, Borenstein E. 2013. Towards a predictive systems-
1105 level model of the human microbiome: progress, challenges, and opportunities. *Curr Opin*
1106 *Biotechnol* 24:810-20.
- 1107 157. Roume H, Heintz-Buschart A, Muller EEL, May P, Satagopam VP, Laczny CC,
1108 Narayanasamy S, Lebrun LA, Hoopmann MR, Schupp JM, Gillece JD, Hicks ND,
1109 Engelthaler DM, Sauter T, Keim PS, Moritz RL, Wilmes P. 2015. Comparative integrated
1110 omics: identification of key functionalities in microbial community-wide metabolic
1111 networks. *NPJ Biofilms Microbiomes* 1:15007.
- 1112 158. Muller EEL, Faust K, Widder S, Herold M, Martínez Arbas S, Wilmes P. 2018. Using
1113 metabolic networks to resolve ecological properties of microbiomes. *Curr Opin Syst Biol.*
1114 8:73-80.

1115

1116 AUTHOR BIOS

1117 **Andrew J McBain** is a Professor of Microbiology at the University of Manchester, UK. He was
1118 awarded his PhD from the University of Cambridge where he studied the human intestinal
1119 microbiota and pro/prebiotics with the Medical Research Council at Addenbrookes Hospital. His
1120 interest in the human microbiome has diversified since moving to Manchester in 1999, to include
1121 body sites such as the skin and the oral cavity. He also maintains research programmes in other

1122 areas of applied microbiology and particularly enjoys multi-disciplinary research. He has supervised
1123 29 PhD graduates and published over 100 papers.

1124

1125 **Catherine A O'Neill** received both her bachelor's degree and PhD from the University of Wales,
1126 Bangor where she studied bacterial biochemistry. Subsequently, she was a research fellow at the
1127 University of Leeds for 5 years before securing her first tenured appointment as a lecturer at the
1128 University of Manchester. Subsequently she was promoted to senior lecturer and then finally to
1129 Professor of Translational Dermatology, the post she currently holds at the University of
1130 Manchester. Professor O'Neill's interests are in using bacteria and their products for the treatment
1131 of skin in health and disease. The laboratory has a very translational focus and has a record in
1132 translating basic findings into human studies via the technology transfer into commercial vehicles.
1133 Professor O'Neill has been involved in this area since 2011.

1134

1135 **Alejandro Amezcua** PhD, graduated from the University of Nebraska-Lincoln (US), with more
1136 than 20 years of experience in various positions in academic (North Carolina State University, US)
1137 and industrial research (Unilever), currently working as Science & Technology Director within
1138 Unilever's R&D group, interested in microbiome innovation in consumer goods and risk-based
1139 approaches to assure product safety because of the importance of balancing the efficacy-safety
1140 continuum, using safety-by-design approaches as the foundation for safe innovation, He has been
1141 working in the microbiome innovation field for 4 years and in the consumer safety and
1142 microbiological risk assessment fields for 15 years.

1143

1144 **Laura J Price** received her Applied Biology BSc (Hons) from Staffordshire University in 2001.
1145 She started her career in Microbiology Quality Assurance for CAMR in 2002. For the following
1146 two years, she was a Leukaemia Research Associate for the MRC. Laura started working at SEAC
1147 Unilever in 2004, where she is currently a Microbiology Risk Assessor. Her role is to independently
1148 assess the consumer safety of new technologies and formulations designed by Unilever R&D. With
1149 the increasing interest in the microbiome as a target for consumer products designed to improve
1150 health and wellbeing, she is part of the Human Microbiome project, which is developing knowledge
1151 on how best to safety assess new technologies. Over the last 4-5 years the project has delivered a
1152 risk assessment framework, methods and data. The interactions of the microbiome and immune
1153 system, and dysbiosis manifesting as human disease, are what particularly interest her.

1154

1155 **Karoline Faust** is a biologist turned bioinformatician who graduated at the Humboldt University in
1156 Berlin and earned her PhD at the Université Libre de Bruxelles under the supervision of Prof. van
1157 Helden. She worked as a postdoctoral researcher at KU Leuven and VIB in the group of Prof. Raes.
1158 She is currently an Assistant Professor, heading the group of Microbial Systems Biology at KU
1159 Leuven since 2016. Her main research interests include the construction and analysis of microbial
1160 networks, the analysis of microbial sequencing data and the investigation of microbial community
1161 dynamics in silico and in vitro. She therefore works at the intersection of microbial ecology,
1162 systems biology and bioinformatics.

1163

1164 **Adrian Tett** is a Senior Research Associate in the Computational Metagenomics group (CIBIO,
1165 University of Trento). He received his Ph.D. from the NERC Centre for Ecology and Hydrology-
1166 Oxford in partnership with Cardiff University. As a Microbiologist and Bioinformatician he
1167 performed postdoctoral research at the BBSRC funded institutes, the John Innes Centre and the

1168 Institute of Food Research. His current work focusses on the microbial communities and subspecies
1169 strain-level determinants associated with human health and disease. He is also developing novel
1170 approaches to explore the population structure, evolutionary history and subspecies diversification
1171 in abundant yet poorly characterised members of the human microbiome.
1172

1173 **Nicola Segata** Ph.D., is Associate Professor at the CIBIO Department of the University of Trento
1174 (Italy). He earned his Ph.D. in Computer Science at University of Trento in 2009 and he then
1175 moved to Harvard School of Public Health for his post-doctoral training where he started studying
1176 the human microbiome with computational metagenomics approaches. He came back to University
1177 of Trento (Department CIBIO) where he started his laboratory in 2013. His laboratory employs
1178 experimental meta'omic tools and novel computational approaches to study the diversity of the
1179 human microbiome across conditions and populations and its role in human diseases. His work is
1180 supported by the European Research Council and by several other European agencies. The projects
1181 in his laboratory bring together computer scientists, microbiologists, statisticians, and clinicians and
1182 focus on profiling microbiomes with strain-level resolution and on meta-analysing very large sets
1183 of metagenomes with novel computational tools.

1184
1185 **Jonathan R Swann** obtained a PhD in Biochemistry from the Department of Biomolecular
1186 Medicine at Imperial College London in 2008. Following his PhD, Dr Swann continued as a
1187 research associate at Imperial College in the area of molecular epidemiology. In 2010 he joined the
1188 School of Chemistry, Food and Pharmacy at the University of Reading as a Lecturer in
1189 Metabonomics. In this role, he developed metabolic phenotyping strategies to study the impact of
1190 nutrition, the gut microbiota, and parasitic infections on mammalian health and disease. In 2015,
1191 Jonathan joined the Division of Computational and Systems Medicine at Imperial College as a
1192 Senior Lecturer in Human Development and Microbiomics. He was appointed Associate Professor
1193 in 2017. He leads a metabonomic-based research programme to understand the influence of gene-
1194 environment interactions on the mammalian metabolic system and their implications for
1195 development, health and disease. His research has a specific focus on the microbiome.
1196

1197 **Adrian M Smith** was awarded a BSc in Biomedical Sciences from Sheffield Hallam University in
1198 2001 and an MSc in Bioinformatics from the same institute in 2002. He worked briefly for GSK
1199 before taking up his current position as Bioinformatician for Unilever R&D in 2005. He has had an
1200 interest in Microbiomics for 9 years due to the initial disruptive nature of the science, and the speed
1201 at which it continues to develop and reveal previously hidden microbial secrets. Most recently he
1202 has had a particular focus on the development of bioinformatics analysis pipelines and visualisation
1203 tools for microbial 'Omics data analysis.
1204

1205 **Barry Murphy** has received education at University College Dublin with Post-Doctoral studies at
1206 the University of Leicester encompassing microbiology, molecular biology and chemistry. A move
1207 to industry saw him establish and manage DNA sequencing laboratories across Europe before
1208 moving to Unilever to lead the microbiome capability group. Having held this position for 5 years
1209 he has an interest in understanding human associated microbial communities to investigate links
1210 between microbial metabolism and cosmetic conditions.
1211

1212 **Mike Hoptroff** is a senior project manager at Unilever with responsibility leading Microbiome
1213 Science and Technology in the UK. He graduated in 1995 from the University of Sheffield and then
1214 moved to research posts in the UK and USA prior to joining Unilever in 1998. Since joining
1215 Unilever he has spent 21 years in Microbiology R&D initially as a research scientist and
1216 subsequently as a project manager. During this time he spent approximately 6 years working on

1217 skin cleansing and hand hygiene (2003-2008), 7 years on scalp microbiology (2009-2016),
1218 including 4 years leading Microbiology R&D in Unilever China and 3 years on Oral Care
1219 microbiology research (2016-). Michael has 13 peer reviewed publications and has led the market
1220 delivery of numerous product technologies.

1221

1222 **Gordon James** originates from Glasgow in Scotland, and was educated at University of Glasgow,
1223 graduating with a BSc and PhD in Biochemistry in 1987 and 1991, respectively. He then did a
1224 postdoctoral fellowship at University of Strathclyde in the area of environmental biotechnology,
1225 during which time he began practicing his favoured disciplines of microbiology and
1226 biochemistry. Gordon joined Unilever R&D in 1993, and in the time since, his main focus has been
1227 using his microbial biochemistry skills to probe the human skin microbiome, mainly to unravel the
1228 origins of axillary (underarm) odour. His current role is to provide scientific leadership to a UK-
1229 based team specialising in this topic on behalf of Unilever's Deodorants category and the global
1230 Science & Technology Platform, Human Microbiome.

1231

1232 **Yugandhar Reddy is a** Research Scientist with Beauty & Personal Care, Unilever R&D. I received
1233 my BSc and MSc in Microbiology and later Ph.D at the Indian Institute of Science, Bangalore. I
1234 was a postdoctoral fellow at the department of Microbiology & Molecular Genetics at University
1235 of Pittsburgh. Prior to joining Unilever, I worked as a Genomics Applications Scientist at Agilent
1236 Inc. My current interests are the Human Microbiome and its relevance for human health and
1237 wellbeing as well as building in vitro models to understand microbial community behaviour. In a
1238 previous role at Unilever I worked at the Safety and Environmental Assurance Center of Unilever
1239 Plc where I was exploring methods and approaches to risk assess Microbiome related technologies
1240 and led an S&T program on Microbial Ecology. I have been in this field for about 7 years to date.

1241

1242 **Anindya Dasgupta** has a PhD in Molecular Biology, Albert Einstein College of Medicine, New
1243 York, USA and is based at Unilever R&D, Bangalore. He is currently exploring scientific insights
1244 that play a crucial role in skin microbiome. The generation of these insights also help in screening
1245 of actives and development of products that have a positive impact on the skin microbiome. A key
1246 factor in this activity is to look at the safety aspect of microbiome modulation.

1247

1248 **Tom Ross** is a Professor in Food Microbiology at University of Tasmania. He was awarded his
1249 PhD from the University of Tasmania in 1994. Since then he has been employed at University of
1250 Tasmania since 1994 as a researcher and teacher concerned with the quantitative microbial ecology
1251 of foods, and leading to my current position. He has supervised ~25 PhD graduates. He has
1252 published >150 international peer reviewed papers/book chapters with his students and colleagues.
1253 His research has also led to numerous software tools that translate his research into 'decision-
1254 support' tools for food safety and preservation that are used by governments and industry
1255 internationally. Those software tools are risk-based, and quantitative. He has been invited to
1256 contribute to many FAO/WHO scientific expert panels concerned with microbial food safety risk
1257 assessment. This background in quantitative risk assessment and microbial ecology led to his
1258 interest in the potential to modify the human skin microbiome and to assess the potentially
1259 associated risks.

1260

1261 **Iain L Chapple** is Head of the School of Dentistry; Research Director of the Institute of Clinical
1262 Science, Birmingham University, UK. He graduated 1986 from Newcastle University. Iain is
1263 former Scientific Editor of the British Dental Journal; Associate Editor of Journal of Periodontal
1264 Research and current Associate Editor of the Journal Clinical Periodontology. He has written 8-
1265 textbooks and 18 book chapters. Iain served the IADR Periodontal Research Group (PRG) as
1266 President (2006-7); Group Chair (2008-1015); Counsellor (2016). He served the European
1267 Federation of Periodontology (EFP) as: Treasurer (2007-2013); Workshop co-chair (2008-current);
1268 Chairman of Scientific Advisory Committee; Editor JCP Digest (2014-2016); Secretary General
1269 (2016-2019). He was British Society of Periodontology President 2014-2015 and awarded the
1270 Tomes medal - Royal College of Surgeons (2011); the IADR PRG Rizzo Award (2001); IADR
1271 Distinguished Scientist in 2018; Special citation award -American Academy of Periodontology
1272 2018. Iain has >200 peer reviewed manuscripts in the international literature.

1273
1274 **William G. Wade** obtained his BSc in Biological Sciences at the University of East Anglia and a
1275 PhD in Microbiology at the University of Wales. He began his career as a Lecturer at the Welsh
1276 National School of Medicine in Cardiff and then moved to a Senior Lecturer appointment at the
1277 University of Bristol. He was appointed to the Richard Dickinson Chair of Oral Microbiology at
1278 UMDS (subsequently King's College London) in 1996. In 2013 he moved to Queen Mary
1279 University of London but returned to King's College London in 2018 to take up his current post of
1280 Professor of Oral Microbiology within the Centre for Host-Microbiome Interactions. He has played
1281 a major role in the characterisation of the oral microbiome, culture of previously uncultivated
1282 bacteria and the development of novel agents for the prevention and treatment of oral diseases. He
1283 has been active in microbiology research for 40 years.

1284
1285 **Judith Fernandez-Piquer** received her BSc in Chemical Engineering and BSc in Food Technology
1286 in Spain, her MSc in Food Safety in the Netherlands in 2007 and her PhD in Food Microbiology in
1287 Australia in 2012. Judith has a broad knowledge of risk assessment and the integration of predictive
1288 microbiology for exposure assessment in foods. After her PhD, she was involved in projects for
1289 Dairy Australia, Walnuts Australia and the Seafood CRC while at the University of Tasmania.
1290 Judith has a strong interest in protecting consumer's health. She joined Unilever SEAC in 2014 as a
1291 risk assessor and led the Human Microbiome project, a programme that aims to enhance the safety
1292 assessment of microbial reprofiling to support innovative technologies in personal care. Judith
1293 started her current role as product safety manager with Upfield, a plant-based food company, in
1294 August 2018.

1295

1296 TABLE 1. Habitat parameters, microbiome functions and intervention strategies for human skin and oral cavity

| | Skin | | | | Oral cavity | | |
|--|---|---|--|---|---|--|--|
| Conditions with microbiome associations | Atopic dermatitis, psoriasis | Acne | Dandruff | Axillary malodor | Caries | Gingivitis | Periodontitis |
| Routine perturbations | Cleansing, moisturizing, use of cream, gels, lotions | Cleansing, use of cream, gels, lotions | Cleansing, use of shampoo | Cleansing, use of antiperspirants and deodorants | Toothbrushing, flossing, use of toothpaste, mouthwash | | |
| Microbiome understanding and potential target mode of action for microbial interventions | <p><i>S. aureus</i> load correlates with atopic dermatitis flares (18)</p> <p>Early colonization with commensal staphylococci provides protection (REF 18, 19)</p> <p>Abnormal expression of antimicrobial peptides (22)</p> <p>Changes in the proportion of bacteria</p> | <p>Outgrowth of <i>C. acnes</i> and overproduction of sebum associated to acne (21, 93)</p> <p>Associated with specific strains of <i>C. acnes</i> (42, 119, 129)</p> <p>Decrease in the Vitamin B12 biosynthesis pathway (132)</p> | <p>Associated with an imbalance of both bacterial and fungal species, with an increase in <i>Staphylococcus</i> sp. and <i>M. restricta</i> (40).</p> <p>Severity of dandruff dependent on the interactions between the host and microorganisms (43)</p> <p>Decreased <i>Propionibacterium</i> and increased</p> | <p>Associated with <i>Corynebacterium</i> species (44)</p> <p>Malodour caused by short and medium chain volatile fatty acids (44)</p> | <p>Changes in oral microbiota composition (28, 29)</p> <p>Outgrowth of acid-tolerant <i>Streptococcus mutans</i> (30), <i>S. sobrinus</i> (96), <i>Lactobacillus</i> and <i>Bifidobacterium</i> (28, 114-117)</p> <p>Increased glycan synthesis and carbohydrate metabolism and reduced lipid metabolism (69)</p> | <p>Changes in oral microbiota composition (28, 29)</p> <p>Subversion of host response at inflamed site, colonization of inflamed tissue by <i>Porphyromonas gingivalis</i> (33)</p> <p>Plaque load and maturity (60)</p> | <p>Changes in oral microbiota composition (28, 29)</p> <p>Sub-gingival biofilm formation is associated with inflammation and bone loss (31)</p> <p>Translocation of oral microbiome to systemic circulation (34-36)</p> <p>Increased metabolic degradation of nutrients and fatty acid metabolism (126, 128)</p> <p>Increased gene</p> |

| | | | |
|--|--|--|---|
| | <p>compared to healthy skin (25, 26)</p> <p>Associated to the fungus <i>Malassezia</i> (106)</p> | <p><i>Staphylococcus</i> abundance (43)</p> | <p>activity related to anaerobic growth conditions (128)</p> <p>Depletion of anti-oxidants, degradation of host cellular components and accumulation of bacterial products (136, 137)</p> |
| <p>Ecological factors specific to the human body site</p> | <p>Bacteriocins and phenol soluble modulins contribute to the maintenance of the niche (56)</p> <p>Skin has a mixture of secretions from different glands and microbiota (137)</p> <p>Host physiological conditions such as sebum and water content are relevant in scalp (43)</p> <p>Higher exposure to moisture, changes in temperature and UV (88)</p> <p>Host factors including skin barrier protein mutations e.g. Filaggrin in AD (20) and mTORC1 changes (increase sebum formation) due, in part, to diet (21)</p> <p>Host immune/inflammatory status (23 - 27)</p> | <p>Food intake, high intake of sugar correlated to production of lactic acid and acidification (REF 30,31)</p> <p>Biofilm formation by attaching to different surfaces (30, 31)</p> <p>Host susceptibility (32)</p> <p>Presence or absence of inflammation (33)</p> <p>Oxygen availability, mechanical stress and saliva flow (6, 61, 86)</p> <p>Antibiotic use (60)</p> <p>Exposure to tobacco smoke (79)</p> | |
| <p>Selected microbiota functions</p> | <p><i>S. epidermis</i> produces AMPs to control the growth of <i>S. aureus</i> (16), serine proteases to inhibit biofilm (16) and fermentation products to inhibit <i>C. acnes</i> (46)</p> <p><i>C. acnes</i> converts sebum to free fatty acids, inhibit colonisation and maintains acidic pH of the skin (46)</p> | <p>Some streptococci generate hydrogen peroxide to inhibit <i>S. mutans</i> (58)</p> <p>Nitrate-reducing bacteria can influence cardiovascular health and blood pressure (59)</p> <p>Some streptococci support enzymatic reactions for nutritional purposes (60)</p> | |

Assessing the safety of microbiome perturbation

Stability




Microbiome composition, specific to each body site, appears to be maintained over the long term

Daily perturbations

The skin and oral microbiomes are impacted every day as part of normal personal care regimes with no imminent adverse effect

Individual variability

Everyone has a different microbiome, requiring this to be accounted for when assessing intervention effects



Assessing the safety of microbiome perturbation

- Are pathogens still prevented from colonising?
- Are environmental conditions still conducive to a functional community?
- Is the effect neutral or positive on the host response?
- Consider the entire community of microbes present, rather than relying on richness alone as a predictor of disease
- Include changes in bacterial load rather than only shifts in composition/proportion

1297
1298

FIG 1. Assessing the safety of perturbations of the skin and oral microbiome

Assessing the safety of microbiome perturbation

Stability



Microbiome composition, specific to each body site, appears to be maintained over the long term

Daily perturbations

The skin and oral microbiomes are impacted every day as part of normal personal care regimes with no imminent adverse effect

Individual variability

Everyone has a different microbiome, requiring this to be accounted for when assessing intervention effects



Innovation for
microbiome
manipulation

Microbial
safety
assessment

Safe
microbiome
perturbation

Assessing the safety of microbiome perturbation

- Are pathogens still prevented from colonising?
- Are environmental conditions still conducive to a functional community?
- Is the effect neutral or positive on the host response?
- Consider the entire community of microbes present, rather than relying on richness alone as a predictor of disease
- Include changes in bacterial load rather than only shifts in composition/proportion